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 1 
Chapter 1 Introduction1 
Foreword 
The central role of dendritic cells (DCs) in the generation of antifungal immunity 
is increasingly appreciated in fungal immunology, and infections caused by the 
pathogenic yeast Cryptococcus is no exception. The interplay between innate 
immunity that initially detects the pathogen and adaptive immunity that is 
essential to combat the infection hinges on DCs (1-7). The function of DCs as 
antigen presenting cells is to 1) gather antigens; 2) discriminate between danger 
and non-danger; 3) process the antigen for presentation, and 4) to prime T-cell 
responses that are specific to the genre of the original danger signal (i.e. virus, 
fungi, tissue damage, etc.) (Reviewed in (8)). In addition to initiation of adaptive 
immunity, there is increasing evidence of a role for DCs in the effector responses 
in the infected tissues, by both continued restimulation of the effector T cells as 
well as the direct effector functions: phagocytosis and intracellular killing of 
fungal pathogens (9-11).  
In this introduction, we first provide a brief overview of Cryptococcus neoformans, 
the related species Cryptococcus gattii, and the generation of protective immunity 
                                                
1 Excerpts of this chapter taken from: 
Eastman AJ, Osterholzer JJ, Olszewski MA. Role of dendritic cell-pathogen 
interactions in the immune response to pulmonary cryptococcal infection. Future 
Microbiol. 2015;10(11):1837-57. doi: 10.2217/fmb.15.92. PubMed PMID: 26597428. 
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to cryptococcosis. We then systematically identify critical evidence 
demonstrating that dendritic cells (DCs) are the architects of anticryptococcal 
immunity, from their initial testing and surveying of the local micro-
environment, to their capacity to initiate naive T cell responses within regional 
lymph nodes, and lastly, to the ability of recruited DC to orchestrate effective 
adaptive immunity directly within infected tissues. In parallel, we will highlight 
cryptococcal virulence factors and alterations in the host cytokine milieu that can 
modulate DC responses and impair host defenses.  
Pathogens and epidemiology 
Two related cryptococcal species, Cryptococcus neoformans (C.neo) and 
Cryptococcus gattii (C. gattii) are etiological agents of cryptococcosis in humans 
and animals: an invasive mycosis capable of disseminating to the central nervous 
system (CNS) with oftentimes-lethal effects. The global burden of cryptococcal 
infections is substantial; one million new cases are diagnosed each year 
associated with a staggering mortality rate of over 60% despite antifungal 
therapy (12). Inhalation of desiccated yeast cells or spores from various 
environmental sources is thought to be the major gateway for cryptococcal 
infections (13, 14). The fungi propagate within the host as encapsulated budding 
yeasts (15, 16). Protective immunity against these highly adaptable opportunistic 
pathogens requires the successful interplay between intact innate and adaptive 
immune responses. Thus, patients with impaired T-cell defenses such as those 
with AIDS (17) and transplant recipients (18) are especially susceptible.  
Although most infected patients have a clearly identifiable 
immunocompromising condition, in the United States, up to 25% of 
 3 
cryptococcosis cases occur in patients without any previously identified 
immunodeficiency (19). Some of these infections are caused by C. gattii (20-22), 
whereas others result from a previously unrecognized cause of 
immunosuppression, as illustrated by recent studies identifying the presence of 
high titers of anti-granulocyte macrophage colony stimulating factor (GM-CSF) 
autoantibodies in the serum and CNS in a subset of infected patients (23-25) 
(reviewed in (26)). The rapidly expanding development and use of newer 
immune modulating agents may also increase susceptibility to cryptococcal 
infections, as best illustrated by the increased incidence of infection in patients 
treated with anti-TNFα antibody therapy (27-31). The identification of these new 
risk factors for primary infection, increasing concerns about recurrent or latent 
disease (32-35), and the limited efficacy of current antifungal therapies, motivate 
new studies focused on protective immunity to cryptococci and mechanisms of 
cryptococcal persistence in the host. A major goal of these investigations is to 
translate these findings into therapeutic strategies that augment host immunity 
while minimizing damage associated with non-protective immune responses. 
The first key: an overview of host defenses against C. neoformans  
The immune response to cryptococci may be divided into two phases: the 
afferent phase where the immune system begins to activate, and the efferent 
phase where cells are recruited to the lung to combat the infection. The afferent 
phase occurs early during cryptococcosis (i.e. the initial interactions between 
C.neo and resident innate immune cells) and is characterized by a subset of cells, 
primarily DC, trafficking to lymphoid organs to sensitize antigen-specific 
lymphocytes. Resident lung macrophages and DCs initiate this immune response 
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by recognizing and ingesting the yeasts (36). The fungus is able to grow within 
and damage the phagolysosome of macrophages (37), while DCs are better able 
to both phagocytose and kill C.neo (10, 11, 38). Antigen processing occurs in the 
DCs as C.neo enters the endosomal/lysosomal pathway (10, 38, 39), which 
coincides with the beginning of DC activation/maturation. Activated DCs 
upregulate MHC class II (MHCII), costimulatory molecules (CD40, CD80, 
and/or CD86), and chemokine receptor CCR7, responsible for homing of DC to 
the lung-draining lymph nodes. In these nodes DCs present C.neo antigen to T-
cells, activate antigen specific T-helper subset promoting their expansion and 
initiating their polarization (40). Perturbations to the afferent phase response, 
mediated by macrophages and DC, may result in death of the host due to acute 
inflammation that damages the lung architecture (41). 
The efferent phase occurs later during cryptococcosis and is characterized by the 
recruitment of additional non-resident cells, such as monocyte populations from 
the bone marrow and antigen-sensitized T cells from the node, while other 
lymphocytes and myeloid cells collectively execute adaptive immunity. In this 
phase, the lung-resident macrophages that initially phagocytosed and 
sequestered– but did not eliminate– the fungi await activation signals from 
antigen-sensitized T cells arriving from regional lymph nodes (38, 42). The T cell-
derived activation signals for the phagocytes are critically dependent upon 
interactions between the newly arrived T cells and non-resident monocyte-
derived CD11b+ DC in the lung environment (43, 44). If these interactions yield 
robust Th1 and Th17 immune responses, then fungal burden reaches a peak 
within the first few weeks of infection and then begins to decline (9, 45). In 
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contrast, non-protective responses such as Th2 immunity, dysregulated 
immunity, or responses that develop in the absence of T cells result in 
persistently elevated pulmonary fungal burdens, progressive fungal expansion 
with dissemination to the spleen and CNS (3, 46-49). Severe impairments in the 
efferent responses, carried out by CD4+ and CD8+ T cells (50-53), result in 
uncontrolled pulmonary growth and dissemination leading to fatal 
meningoencephalitis in humans (17, 35, 54, 55) and mouse models (53, 56-59). 
DCs, as the bridge between innate and adaptive immunity (reviewed in (60)), are 
the lynchpin linking these afferent and efferent responses. The factors 
influencing the outcome of DC:T cell interactions will be further detailed in the 
following sections. 
The second key: DCs in the context of murine models and human disease 
Much of the information provided in the preceding overview of host defense was 
obtained using murine models of cryptococcal infection. In the more detailed 
information about DC phenotype and function to follow, it will be helpful to 
understand that different mouse models of cryptococcosis can be employed to 
mimic distinct clinical patterns observed in human patients. These can be 
modeled by selecting the appropriate strain of Cryptococcus, the magnitude of 
inoculum, or the route of infection. These strategies can also be combined with 
manipulations of host molecular or cellular components, including the genetic 
background of the mouse. For example, the highly pathogenic strain H99 is 
almost uniformly lethal in all mouse strains (reviewed in (61)); thus, 
manipulation of its virulence factors sheds light on the contributions of various 
microbial factors on host immunity (see below). Conversely, infection with less 
 6 
virulent strains of Cryptococcus (JEC21, 52D) into resistant (CBA, BALB/c) or 
susceptible (C57BL/6) strains of mice facilitates investigations into the cellular 
and molecular mechanisms determining whether infections are cleared, persist in 
a contained state, or lethally progress.  
Observations in human patients have directed murine modeling of 
cryptococcosis, which has identified T cells, and their associated cytokine 
responses, as important “downstream” determinants of adaptive immune 
responses against the organism. Both CD4+ and CD8+ T cells contribute to 
adaptive immunity, as studies in mice lacking either or both cytotoxic and helper 
T cells show significant impairment in anti-cryptococcal host defenses (51-53, 59, 
62, 63). Mice with both T cell subsets, but deficient in components of the IFNγ or 
TLR9 signaling pathways, succumb to infection with a milder strain of C.neo 
earlier and/or at greater numbers than their wild type counterparts (64-68). 
These observations indicate that T cells alone are necessary but not sufficient to 
mount a protective immune response. Hallmarks of protective T-cell-mediated 
immunity to C.neo include: a) robust production of Th1 and Th17 cytokines, 
particularly, IFNγ, TNFα, and IL-17A; b) the presence of classically activated 
(M1) macrophages and DCs (DC1); and c) progressive clearance of infection and 
limited dissemination of the microbe (3, 45, 47, 48, 64, 66, 69-75). Conversely, 
non-protective immunity to C.neo infection in mice is identified by: a) increased 
Th2 cytokine production, particularly IL-10, IL-4, IL-5, and IL-13; b) the presence 
of alternatively activated macrophages (M2) with resultant YM-1/2 crystal 
deposition; c) eosinophilia and high serum IgE; and d) progressive growth of the 
microbe in the lungs followed by multi-organ dissemination (3, 32, 76-80). Non-
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protective immune responses may result in either a progressive infection and 
lethal dissemination (17, 18, 55), or a low-level persistent lung infection where 
the microbe is contained but not cleared by the immune system and may re-
activate upon loss of immune function (32-35). Thus, the importance of murine 
models in identifying these unique T cell mediated immunophenotypes led to 
many of the additional investigations (identified throughout this review) that 
have dissected and delineated the role of DC in orchestrating these responses. 
This introduction incorporates data about DC from both human and murine 
studies. Similar to mice, human T cell responses to C. neoformans– rather than 
being uniformly polarized– are typically of mixed polarization (i.e. not 
completely Th1 or Th2 as is often observed in extreme polarization models 
developed in mice), and determined by the net balance between several 
potentially competing cytokine profiles. Broad studies of these cytokine profiles 
demonstrate that low levels of Th1 cytokines (IFNγ and TNFα) are associated 
with a poor outcome in patients with cryptococcosis (81, 82), consistent with 
findings using murine models (3, 45, 57, 64, 66, 73, 83-85). In addition, limited 
evidence suggests that infected patients displaying features of a strong Th2 bias 
also do poorly (86, 87). Whether DC are involved in skewing these T cell profiles 
in human patients is uncertain and not well studied. However, one recent study 
demonstrated that a particularly virulent strain of C. gattii that infects 
immunocompetent individuals will suppress the host DC’s TNFα production 
(88) which may help explain in increased risk of cryptococcosis in patients 
receiving TNFα blocking monoclonal antibody therapy for autoimmune 
disorders (27-31). In addition, recent reports have identified autoantibodies 
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against GM-CSF, an important DC growth and differentiation factor, in a subset 
of patients with cryptococcosis who had not previously been identified as 
immunodeficient (23, 24). Collectively, the literature supports that murine 
models recapitulate many features of human host defenses against C. neo. This 
introduction will proceed to illustrate the integral role of DC in the immune 
responses against the organism. 
The master key: subsets and nomenclature of dendritic cells 
During infection, the composition of the host DC population changes 
dramatically as resident DC migrate to peripheral lymphoid organs and 
additional DCs, derived from recruited DC precursors, accumulate at the site of 
infection (see Table 1-1 and Figure 1-1). We refer to conventional DCs (cDCs) 
simply as DC, and the findings discussed do not represent plasmacytoid DC 
unless explicitly stated otherwise. Two separate subsets of DC residing in 
uninfected mouse lungs are identified and distinguished based on surface 
expression of CD103 and CD11b molecules: CD103+/CD11b- DC and CD103-
/CD11b+ DC (for all subsets described here, see Table 1-1 for the equivalent 
human DC subset markers). Both subsets express CD11c, MHCII, and feature 
low levels of autofluorescence by flow cytometry (89-91). These DC are distinct 
from resident alveolar macrophages, which are large, autofluorescent, 
CD11c+/CD11b-, MHCIIlow cells residing in alveolar spaces (44, 57, 90, 92-94).  
 9 
 





Figure 1-1 Mobilization and trafficking of myeloid cells 
in different compartments during cryptococcosis.    
An increase in DC numbers in the regional 
thoracic lymph nodes 1 day post infection 
(dpi; top panel) suggests the immediate 
migration of resident DC from the lung.  A 
second peak at 10 dpi coincides with a 
marked accumulation of Ly-6Chigh 
monocytes and monocyte-derived CD11b+ 
DC in the lung (2nd panel), some of which 
may migrate to the node.  The observed 
peak of Ly-6Chigh monocytes in the lung 
(2nd panel) coincides with similar peaks in 
the blood (3rd panel) and bone marrow (4th 
panel) suggests inter-compartmental 
“communication” between lung, blood, and 
marrow to meet the need for additional 
lung DC in response to cryptococcal 
infection. Data were generated from 
published ((44) and (92)) and unpublished 




Cryptococcal infection triggers the rapid and substantial recruitment of Ly-
6Chigh CD11b+ inflammatory monocytes arriving from the bone marrow to 
subsequently differentiate into CD11b+ monocyte-derived DC and exudate 
macrophages (ExM). The latter two populations are CD11c+, CD11b+, and 
MHCII+ but ExM can be distinguished from the DC by their larger size, higher 
autofluorescence, and lower MHCII expression (44, 90, 92, 95). The 
differentiation of these CD11b+ DC from Ly-6Chigh monocytes and their CCR2 
dependent accumulation suggests these DC are related to and likely encompass a 
subset of TNFα-iNOS producing DCs (TIP-DCs) that have been shown to be 
important effector microbicidal cells in Listeria monocytogenes (96) and Histoplasma 
capsulatum infections (43, 44, 92, 97-100). Additional subsets of DCs found in the 
lymph nodes express distinct combinations of CD4, CD8, and the endocytic 
receptor Dec205; the CD4+8−DEC-205−, the CD4−8−DEC-205− and the 
CD4−8+DEC-205+ subsets are node resident DCs, and these can be distinguished 
from other DCs that have trafficked to the lymph node by expressing lower 
amounts of costimulatory molecules, lacking CD11b expression and lacking 
CCR7 expression (101, 102). Within the lymph node, Langerhans DCs may play a 
role, and are defined as DEC205low/FSChigh/CD8αlow/CD11blow (40, 91). 
DCs as gatekeepers: pathogen recognition and DC activation 
All fundamental DC functions during microbial infections, including 
cryptococcosis, are initiated with recognition of pathogens (Figure 1-2). This  
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Figure 1-2 Key interactions of immune cells and C.neo during cryptococcal infection.  
A) 1. DCs recognize and phagocytose C.neo in an infected lung and process the 
antigen, triggering DC maturation and migration to the lung-associated lymph 
nodes (LALN) through CCR7-CCL19/21 interactions (afferent phase immune 
response). 2. In the LALN, naïve T cells interact with mature DCs. DCs present 
antigen on MHCII, express costimulatory molecules (CD40/CD80/CD86), and 
secrete pro-Th1 cytokines such as IL-12. Cognate T cells become Ag-sensitized 
and proliferate. They do not yet produce cytokines. 3. Ag-sensitized T cells traffic 
to the lungs (efferent phase immune response), and they interact once again with 
DCs in the lung. They do not proliferate at this stage, but they do begin to secrete 
cytokines, directing the immune cells in the lungs. B) CD4+ T cells within the 
lungs do not proliferate, but do make cytokines such as IFNγ. C) CD4+ T cells 
within the LALN are actively proliferating, but do not upregulate cytokine 




occurs via a system of receptors defined as pattern recognition receptors (PRRs). 
PRRs are intra- and extracellular molecules designed to detect a matching set of 
microbial pathogen associated molecular patterns (PAMPS) or damage 
associated molecular patterns (DAMPS) released by injured tissues. The PRRs 
trigger signaling cascades that result in DC activation and subsequent 
interactions that orchestrate behavior of other cells of the immune system. 
Specifically, PRR signaling is crucial for: a) antigen uptake; b) discrimination 
between relevant and non-relevant antigens; c) processing of antigens for 
presentation; d) activation/maturation; and e) generation of signals for priming 
and execution of the adaptive immune response by DCs. Major types of PRRs of 
particular or emerging importance to cryptococcal infection are the Toll-like 
receptors (TLRs), Nod-like receptors (NLRs), scavenger receptors, C-type Lectin 
receptors (CLRs), and the functionally-related complement receptors (discussed 
in (103)). While these receptors are intimately tied to DC activation, microbes 
frequently employ counterstrategies to evade detection by these receptors or co-
opt them to manipulate host responses. 
PRRs: TLRs, NLRs, and dectins 
TLRs are expressed on the cell surface and in endosomes or phagosomes that 
recognize various types of PAMPs. TLR2 and TLR4 are active during 
cryptococcal infection and bind cryptococcal polysaccharides with the help of 
CD14 and CD11/18 (104, 105). LPS, the canonical TLR4 ligand, can be found in 
the polysaccharide capsule of C.neo, likely due to the ubiquity of LPS and the 
stickiness of the capsule (reviewed in (106)). However, despite its involvement in 
the initial immune response, studies in TLR4-deficient mice show that it is 
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ultimately dispensable to anti-cryptococcal immunity (107, 108). Studies show 
that the necessity for TLR2 ranges from completely unnecessary (108), to slightly 
beneficial (107), to conferring an obvious survival advantage (109), which may be 
confounded by each study utilizing different cryptococcal strains (and thus 
inconsistent capsule thicknesses, which likely influences TLR2 stimulation), 
inoculum doses, and infection routes. In contrast, TLR9 is of great importance to 
the generation of protective immunity to C.neo (65, 67, 68, 110, 111). Defective 
immunity in response to C.neo in the absence of TLR9 can be attributed to failed 
DC activation and impaired myeloid cell recruitment from the bone marrow (65). 
Cryptococcal DNA is a critically important TLR9 ligand, as demonstrated by 
Nakamura et al. 2008 and Tanaka et al. 2012 (68, 112). CpG DNA, the canonical 
TLR9 ligand, is taken up by DCs and directed to the lysosome where it interacts 
with TLR9 (113). In side-by-side in vitro experiments, fluorescently-labeled CpG 
or cryptococcal DNA from acapsular mutants displayed similar trafficking 
patterns in bone marrow-derived DCs (BMDCs) via fluorescence microscopy, 
and elicited similar production of pro-inflammatory cytokines and surface 
expression of costimulatory molecules from BMDC (68). Similarly, MyD88, as the 
adaptor molecule for canonical signaling through TLRs 2, 4, and 9 (114-116) and 
also IL1R, is required for mounting effective immune responses against 
cryptococcal infection; MyD88 deficiency during cryptococcal infection induces 
equivalent defects as TLR9 deficiency (65, 67, 107, 109, 111). This response is 
characterized by diminished Th1 elements, elevated Th2 elements, and reduced 
numbers of CD4+ and CD8+ T cells in lungs, nodes, and spleen, and alternative 
activation of macrophages (67). 
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Little is published about NLRs during cryptococcal infection. Recent work from 
Cordero et al. shows that acapsular mutants of C.neo activate the NLRP3 
inflammasome in peritoneal and bone-marrow derived macrophages, and 
NLRP3 activation resulted in decreased cryptococcal replication and escape from 
macrophages in vitro (117). Further investigations with other C.neo strains in 
mice, and more corresponding data from human studies, are needed to clarify 
the role of NLR and the downstream inflammasome activation in the generation 
of protective responses to C. neo. 
Dectin-1, required for β-glucan recognition and immunity against C. albicans and 
A. fumigatus, is not required for anti-cryptococcal immune responses (118). 
Consistent with this finding, a recent study shows that Dectin-2 deficient mice 
have similar fungal burden as infected WT mice (119). However, infected Dectin-
2-deficient mice display numerous Th2 hallmarks: increased IL-4, IL-5, and IL-13, 
increased mucin, lower TNFα and IL-12 production, and decreased 
costimulatory molecule expression (119). This phenotype is most often associated 
with impairments in cryptococcal clearance, yet none were observed in this 
study. Thus while dectin-2 signaling has clearly some effects on the phenotype of 
the immune response its net effect on fungal clearance appears to be neutral. 
Scavenger and mannose receptors and immune modulation in cryptococcosis 
Numerous scavenger receptors aid macrophages and DCs in priming protective 
immune responses to C.neo. Using an in vitro shRNA screen of mouse 
macrophages during cryptococcal stimulation, Means et al. demonstrated that the 
scavenger receptors CD36, SCARF1 and SCARB2 promote IL-1β generation and 
are protective during cryptococcal immune responses (120). Conversely, studies 
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using Scavenger Receptor A (SRA)-deficient mice demonstrated that SRA 
signaling contributed to non-protective immunity via decreased DC and CD4+ T-
cell accumulation, decreased DC1 polarization, and an increase in the hallmarks 
of non-protective immune responses including eosinophilia and IL-10 
production (121). This suggests that C.neo exploits SRA to modulate the host 
response, promoting responses that favor survival and persistence of the 
microbe. The roles of other SR family members in the development of protective 
immunity to cryptococcal infection remain to be elucidated.  
The mannose receptor (CD206) represents a double-edged sword for anti-
cryptococcal immunity: it is necessary for the generation of protective immunity 
to C.neo (122), but its overexpression is also a hallmark of alternative activation in 
macrophages and DCs (reviewed in Gordon 2003 (123)), which contribute to non-
protective immunity to C.neo (79). CD206 on the surface of macrophages and 
DCs binds cryptococcal mannoprotein (MP) on the cell wall of acapsular C.neo 
(10, 124); the addition of zymosan or glucan particles to macrophages in culture 
can bind competitively to CD206 and prevent uptake of C.neo (124). BMDCs 
derived from CD206-deficient mice did not stimulate robust T-cell expansion or 
activation (relative to WT mouse-derived BMDCs) (122). However, uptake of 
C.neo was unhindered in CD206-deficient BMDCs relative to WT BMDCs, 
suggesting that another phagocytic receptor may be compensating for the loss of 
CD206 in C.neo uptake (122). Stimulation of macrophages and BMDCs through 
CD206 induced TNFα mRNA and protein production (10, 124), but in other 
models, it inhibits IL-12 production and promotes IL-10 production (125, 126). 
Thus the effects of CD206 signaling appear complex and it is possible that high 
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CD206 expression, linked with alternative activation of phagocytes, promotes the 
intracellular survival, and not killing, of C.neo (127). Together, these studies show 
that CD206 may contribute to both protective and non-protective responses, 
depending on other signals that occur during DC-C.neo interactions. More work 
to clarify the role of CD206 in T-cell activation and CD206 signaling pathways is 
necessary to more fully understand its complex role in protective immune 
responses to C.neo.  
The fungus strikes back: cryptococcal virulence factors influence dendritic 
cells 
Several cryptococcal virulence factors interfere with the development of 
protective immune responses in the infected host. The majority of these effects 
are linked to their interference with antigen presenting cells (APCs) of myeloid 
lineage including DC, macrophages, and their monocyte precursors (Figure 1-3). 
These cells share many functional and metabolic pathways, and thus the 
virulence-associated genes not surprisingly affect these mononuclear APCs in a 
similar fashion. Functional pathways commonly affected by fungal virulence 
factors include those associated with pathogen uptake and degradation, APC cell 
activation/maturation, classical versus alternative polarization, cytokine 
production, and crosstalk of APC with the antigen specific T-cells. As a 
consequence of cryptococcal interference with these pathways, C.neo not only 
directly alters innate functions of DCs and other APCs, but also induces 
profound down-stream effects on the adaptive/efferent arm of the immune 
response. For example, cryptococcal laccase (128-130), virulence-associated 
DEAD-box protein (VAD1) (131, 132), cryptococcal Hsp70 homologue Ssa1 (133),  
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Figure 1-3 Host and pathogen-derived factors can skew DCs to DC1 or DC2 polarization.   
Activated DCs are capable of becoming DC1 cells, which promote protective Th1 
T cell responses in C.neo-infected mice, or DC2 cells, which promote non-
protective Th2 T cell responses in C.neo-infected mice.   Note that this schematic 
is over-simplified as many DC, particularly in human disease, exist on a 
spectrum between DC1 and DC2.  The relative strength of DC1 and DC2 
pathways is influenced by factors derived both from the host and the pathogen 
and it is the relative balance between these pathways that determines the net DC 
phenotype . DC1 express high iNOS, MHC Class II, costimulatory molecules, 
and pro-Th1 cytokines whereas levels of Arginase, Fizz1, and other DC2 markers 
are low.  Conversely, DC2 express a reciprocal pattern and are more associated 
with pro-Th2 cytokine expression. 
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and phosphatidylinositol 4-kinase (PIK1), a ubiquitin-like protein (RUB1), and a 
cation ATPase transporter (ENA1) (134) were shown to interfere with the innate 
APC pathways upstream of their effects on the development of adaptive 
immunity. While future studies are needed to dissect specific interactions of 
these factors with DC, some cryptococcal components have been already shown 
to modulate maturation and polarization of DC and their monocyte precursors. 
Among these factors are capsular polysaccharides, mannoproteins, and 
cryptococcal urease, laccase, and Ssa1. 
Polysaccharide capsule and GXM 
The C.neo polysaccharide capsule is a major virulence factor that inhibits 
phagocytosis, as illustrated by acapsular mutant strains of C.neo being avirulent 
and readily ingested by phagocytes in mice (135-138). The addition of capsular 
material to co-cultures of myeloid cells with acapsular C.neo prevents 
phagocytosis of the acapsular C.neo (139). The polysaccharide capsule, comprised 
primarily (80%) of glucuronoxylomannan (GXM) (140-147), exerts effects on 
dendritic cell activation in both human and murine monocytic cells. In vitro 
exposure of murine CD11c+ splenic DC to C.neo polysaccharide capsule 
decreases their secretion of TNFα and chemokine ligands (CCL3, CXCL10, 
CCL4), and impairs CCR7 expression (148). 
Monocytes encountering acapsular C.neo in vitro upregulate MHC II and 
costimulatory molecules similar to those induced by treatment with LPS (44, 
149); in contrast, these effects are not observed when monocytes are exposed to 
encapsulated organisms (150, 151). In work performed with human tissue, the 
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addition of purified capsule component GXM to human monocytes treated with 
acapsular C.neo modulated their function as evidenced by their: a) decreased 
TNFα and IL-1β production (152); b) increased IL-10 secretion (150): c) decreased 
surface expression of MHCI and MHCII; and d) impaired phagocytosis of 
acapsular C.neo (151). However, when human monocytes were incubated with 
encapsulated C.neo treated with anti-GXM, the human monocytes were 
nonetheless unable to upregulate MHCII or costimulatory molecules (151), 
suggesting that another, as of yet unidentified component(s) of the capsule, can 
suppress MHCII expression. The cryptococcal polysaccharide capsule is thus an 
extremely important and incompletely understood virulence trait with important 
effects on DC activation. 
Mannoprotein 
Cryptococcal mannoprotein (MP, in two isoforms, MP1 and MP2) promotes 
CD4+ T cell stimulation (153, 154), although it was initially unknown which 
phagocyte was primarily responsible for presenting it to T cells. Early studies 
showed that MP induced replication in human PBMCs (155) and enhanced IL-12 
secretion from human monocytes (156). Later work showed that multiple lectin 
receptors on DCs were responsible for MP uptake via MMR (157), and that 
uptake induced IL-2 production from CD11c+ splenic DCs (158) (reviewed in 
(159)). However, the effects of MP on DC maturation differ with stimulant 
duration, model system, and the presence or absence of other 
immunostimulatory molecules. MP1 and MP2 were shown to induce DC 
maturation over 48 hours at concentrations between 5 and 20 %g/mL via 
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upregulation of costimulatory molecules, MHCI and MHCII, and down-
regulation of phagocytic receptors comparable to LPS in human PBMCs 
differentiated to DCs using IL-4 and GM-CSF (157). In another study, a mixed 
population of MP1 and MP2 at a concentration of 50 %g/mL for 24 hours 
maintained DC immaturity in murine BMDCs differentiated with GM-CSF and 
IL-4 when compared to LPS stimulation (84). Finally, the addition of TLR 
receptor ligands CpG DNA, dsRNA, and others (discussed above) to MP 
preparations in vitro resulted in greatly enhanced DC activation (160). Thus, the 
context in which DCs encounter MP may be a deciding factor in whether its 
effects are immunostimulatory or immunosuppressive. 
Urease, laccase, and Ssa1 
The cryptococcal virulence factor urease, an extracellular enzyme that 
hydrolyzes urea, promotes CNS dissemination and facilitates microvascular 
sequestration of C.neo in the brain (161). The cryptococcal virulence factor 
laccase, necessary for melanin production and inflammatory mediators such as 
prostaglandins, is also necessary for CNS dissemination (128-130, 162-164). In 
some strains of C.neo, the cryptococcal HSP70 homologue Ssa1 (a major antigen 
for the antibody response, and often found in cryptococcal capsule) controls the 
expression of laccase, and thus all the hallmarks of laccase-dependent virulence 
(165). Ssa1 is also a virulence factor in its own right: independent of its control of 
laccase in some strains, but it is unknown what its role is during the innate and 
adaptive response (133). Mice infected intratracheally with either a urease-
deficient strain or laccase-deficient strain of C.neo have fewer hallmarks of non-
protective Th2 immunity: lower pulmonary fungal burden, less extrapulmonary 
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dissemination, dramatically less eosinophil recruitment, and less YM-1 crystal 
deposition (49, 130). Furthermore, the urease-deficient strain accumulated fewer 
immature DC in the lung-associated lymph nodes (LALN) compared to wild-
type C.neo (44), which was consistent with the hypothesis that urease promoted 
development of non-protective immunity by interfering with maturation of DC 
in the C.neo infected lungs. These findings were also consistent with other mouse 
studies showing a strong association between immature DC phenotype and the 
development of non-protective Th2 immune responses to C.neo (47, 84). As we 
will discuss in the next section, the critical role of DC in anti-cryptococcal 
defenses is being strengthened by the accumulating evidence linking impaired 
DC numbers and activation with higher fungal burdens in the lung and 
increased risk of lethal CNS dissemination. 
Host factors that influence dendritic cells 
Pro-DC1 and pro-DC2: IFNγ and IL-4 
IFNγ  activates DCs to become classically activated (DC1), thus priming 
Th1/Th17 immune responses (reviewed in (166)) , while IL-4 activates DCs to 
become alternatively activated (DC2), thus priming Th2 immune responses (167). 
Throughout the in vitro experiments in this dissertation, we will use IFNγ as the 
pro-DC1 stimulus and IL-4 as the pro-DC2 stimulus, as these are the 
predominant pro-DC1 or pro-DC2 cytokines found during pulmonary 
cryptococcal infection (3, 7, 57, 66, 72, 78, 80, 97, 168-170), and thus are the 
biologically relevant stimuli for our modeling of DC activation during C.neo 
infection (as opposed to more standard pro-DC1 activatiors, such as LPS). While 
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IL-4 is generally considered to be non-protective in cryptococcal infections, we 
cannot ignore recent studies showing that IL-4 receptor signaling can 
temporarily promote C.neo control during the very early, but not later, phases of 
cryptococcal infection in mice (119, 171). However, with our strain of C.neo 
(primarily 52D), in our mouse background (primarily CBA/J, with some Balb/c), 
and at the relevant time points in our extensively characterized model (3, 7, 14, 
and 28 dpi) (45, 84, 85), IL-4 is correlated to DC2 activation and nonprotective 
Th2 immune responses; thus we feel justified in its usage as pro-DC2 cytokine in 
vitro.  
GM-CSF in human cryptococcosis patients 
Granulocyte macrophage colony stimulating factor (GM-CSF) is a cytokine 
instrumental in generating DCs (reviewed in (172)). As noted above, GM-CSF is 
increasingly appreciated as a necessary factor in anticryptococcal immunity as 
evidenced by anti-GM-CSF autoantibodies, such as those found in patients who 
either have or go on to develop pulmonary alveolar proteinosis, correlating to 
higher rates of cryptococcosis with either C.neo or C. gattii (23). Furthermore, the 
presence of anti-GM-CSF autoantibodies results in higher rates of dissemination 
of C. gattii to the CNS in human patients (24). The data generated in mice and 
rats are consistent with the requirement of GM-CSF for generation of protective 
response; Chen et al. showed that both mice and rats deficient in GM-CSF have a 
significantly higher pulmonary fungal burden at the efferent phase of the 
immune response and in association with some impairment in T cell numbers 
and cytokine responses (25, 173). Of note, TNFα production in infected GM-CSF-
deficient mice was significantly reduced relative to wild type mice (25). 
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Importance of TNFa in human patients and in mouse models of cryptococcal infection 
Several different lines of evidence point to TNFα as a crucial cytokine in the host 
response to C.neo. Along with IFNγ, TNFα is the major protective biomarker in 
C.neo infected patients (81, 82). Furthermore, human patients that are receiving 
TNFα blocking antibody therapy (Infliximab, Etanercept, Adalimumab) and who 
are otherwise immunocompetent, are at increased risk of C.neo infection (30, 83). 
The resistance of CBA/J mice to strain 52D can be overcome by TNFα depletion 
(45, 73, 84, 85). Conversely, C57BL/6 mice (susceptible) given an adenoviral 
vector expressing TNFα prior to intratracheal cryptococcal infection increased 
their number of accumulated monocytes, decreased the numbers of accumulated 
eosinophils, displayed progressive clearance of the infection similar to CBA/J 
mice, and increased the hallmarks of Th1 response relative to mice that were 
infected with Cryptococcus that received a control adenoviral vector (174). In 
addition to host-specific effects on TNFα-production, different strains of C.neo 
also vary in the amount of TNFα elicited from immune cells derived from the 
same strain of mice. Strains of C.neo that have been induced to express high 
melanin via culture in asparagine salts agar induce baseline levels of TNFα 
production from cultured alveolar macrophages in vitro, while in vivo, naturally 
occurring high-melanin-producing strains of C.neo yield levels of TNFα 
comparable to uninfected mice in BAL fluids (175, 176). Similar effects were 
observed with C. gattii strains that cause invasive disease in patients with no 
known immunodeficiencies. Infection resulted in down-regulation of the host 
TNFα response and skewed the adaptive immune response away from 
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Th1/Th17 (88, 177). Thus, the removal or addition of TNFα is sufficient to 
fundamentally alter whether C.neo is or isn’t cleared. 
TNFα and DCs during C. neoformans infection 
Studies using murine models consistently identify the first 7 days of infection 
while the afferent immune response develops as the period in which TNFα 
signaling has the most profound effect on the generation of protective immunity 
against C. neo. (45). Transient depletion of TNFα before day 7 post-infection by 
injection of TNFα blocking antibodies induces profound, long-term effects on 
anti-cryptococcal immunity, while short-term depletions of TNFα after day 7 of 
infection do not prevent development of protective immunity (45). In other 
studies, administration of exogenous human TNFα to mice during days 1-3 post-
infection was sufficient to extend survival times by over 30% (73). The temporal 
relationship between TNFα production (or blockade) and the afferent immune 
response provides important evidence that TNFα is critically associated with 
priming of the immune response and that DCs, as primers of the immune 
response, may represent the cell subset most significantly affected by TNFα 
signaling. While early studies did not distinguish between macrophages, DCs, 
and monocytes (45), they noted a dramatic decrease in mononuclear phagocyte 
accumulation during TNFα depletion, which resolved upon recovery of TNFα 
levels (45, 84, 85). Further experiments showed a correlation between the 
phenotype observed when mice were depleted of TNFα and the phenotype 
observed when infected mice had received adoptively transferred immature 
dendritic cells pulsed with cryptococcal mannoprotein prior to infection. Mice 
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receiving adoptively transferred immature DC developed non-protective Th2 
immunity in subsequently infected recipient mice relative to infected mice that 
received LPS- and MP-pulsed mature DC (84). Thus, DC maturation and/or 
polarization are of the utmost importance in generation of protective immunity 
to C.neo. 
“Training” of dendritic cells against C. neoformans 
A series of novel paradigm-shifting studies demonstrated that epigenetic 
modifications substantially influence patterns of DC and macrophage activation 
and gene expression (reviewed in (178)). Epigenetic modifications are 
biochemical modifications (methylation, acetylation, phosphorylation, among 
others) added to DNA or histones that stably regulate gene expression by 
altering a gene’s accessibility to the cell’s transcriptional machinery (reviewed in 
(179)). These modifications can be either activating or suppressive. Histone 
acetylation is typically activating, while DNA hypermethylation in promoter-
region CG islands is transcriptionally repressive. Histone methylation can be 
either activating or repressive depending on the residue of the histone tail that 
receives the methyl group(s). Histone methylation marks are deposited by 
histone methyltransferases (reviewed in (180)) and removed by histone 
demethylases. DNA methyltransferases add methyl groups to DNA, while 
demethylation is induced by cytidine deaminases or Tet proteins, (reviewed in 
(181)). Many of the signaling pathways, protein complexes, and enzymes that 
affect DC and macrophage polarization through epigenetic modification are 
beginning to be elucidated. The studies enumerated below provide evidence that 
these pathways can modulate DC responses to cryptococcal infection. 
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TNFα signals through MAPK and NFκB pathways (reviewed in (182)), and 
epigenetic modification of key immune genes is known to occur through both the 
MAPK (183, 184) and NFκB (185) signaling pathways. Exciting new work from 
Diermeier et al. has shown that TNFα signaling directly changes chromatin 
structure around NFκB-associated gene regions (186). MAPK signaling has been 
shown to be required for IL-1β production in DCs (184) and MHCII expression in 
macrophages (187). NFκB signaling has been shown to epigenetically regulate 
the promoter of the chemokine eotaxin (185), and NFκB signaling has been 
linked to activities of the histone methyltransferase MLL1, which forms a multi-
protein complex instrumental for IL-12p40 epigenetic regulation in DCs (188) 
and at numerous other promoters in myeloid cells (189). Our studies showing 
that cryptococcal clearance is impaired by TNFα signaling blockade during the 
first week post-infection highlight the critical importance of early TNFα 
signaling in the transition between innate and adaptive immune responses 
mediated by DCs to the organism. Our yet unpublished results suggest that this 
transition may be highly influenced by TNFα-induced epigenetic modifications 
to key DC1 and DC2 genes. Taken together, these studies suggest that TNFα 
signaling can epigenetically modify DCs at critical regions of DC1 and DC2 
genes during cryptococcal infection, and is a potential mechanism behind the 
long-term effects of short-term TNFα depletion in cryptococcal infection. 
Epigenetic modifications induced by TLR signaling may also contribute to the 
paramount importance of PAMP/TLR signaling in cryptococcal infection. TLRs 
signaling through the MyD88 adaptor protein use the NFκB and MAPK 
pathways, similar to TNFα signaling (above), and affect the epigenetic regulation 
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of inflammatory genes in monocytes (190-192). In work by Weinmann et al., 
chromatin remodeling and subsequent transcription factor binding to the 
promoter region of IL-12p40 in murine macrophages depended upon TLR 
stimulation (193, 194). Further, Mycobacterium tuberculosis induced IL-12 
production from DCs specifically through ligation of TLR9, while M.tb 
stimulation of macrophages, which occurs through TLR2, caused minimal IL-12 
production. This was due to chromatin remodeling around the IL-12p40 
promoter stimulated by TLR9, but not TLR2, signaling (195). As discussed above, 
CpG DNA signaling through TLR9 critically contributes to IL-12 production in 
mouse models of cryptococcosis (110), and the loss of TLR9 impairs DC 
responses during cryptococcal infection (65). Thus, TLR signaling may 
epigenetically regulate pro-Th1 gene expression in DC response to C.neo.  
Summary 
Protective immunity to C.neo requires robust T cell responses, and this is 
preceded by the production of key protective pro-inflammatory cytokines TNFα, 
IL-12, GM-CSF, and IFNγ. These responses are primed by classically activated 
DCs in the node and in the infected lung tissue where effector DC also play a role 
in phagocytosis and killing of C.neo. DCs in cryptococcal infection must 
overcome alternative activation or immaturity, which is promoted by a vast 
repertoire of cryptococcal factors. It is possible that epigenetic training of DC 
during cryptococcal infection aids DCs in maintaining DC1 programming in the 
infected lungs, lymph nodes, and any sites of dissemination in order to prime 
effective T cell responses. 
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This dissertation investigates how both C.neo and host factors can modulate the 
afferent immune response, and under what circumstances these factors impact 
the developing efferent immune response. The overarching hypothesis is that 
crosstalk between host defense signals and fungal factors during the afferent 
immune response to C.neo by modulating DC activation and/or polarization 
directly impacts the developing adaptive response to become either protective or 
non-protective. This dissertation will primarily focus on the roles of a specific 
cryptococcal factor, the heat shock protein 70 homologue Ssa1, on the microbial 
side, and the cytokine TNFα on the host side, to gain better insights on the 













Chapter 2 Cryptococcal HSP70 homologue Ssa1 
contributes to pulmonary expansion of C. neoformans 
during the afferent phase of the immune response by 
promoting macrophage M2 polarization2 
Abstract 
Numerous virulence factors expressed by C. neoformans (C.neo) modulate host 
defenses by promoting non-protective Th2-biased adaptive immune responses. 
Prior studies demonstrate that the HSP70 homologue, Ssa1, significantly 
contributes to serotype-D C.neo virulence through the induction of laccase, a Th2-
skewing and CNS-tropic factor. In the current study, we sought to determine 
whether Ssa1 modulates host defenses in mice infected with a highly virulent 
serotype A (serA) strain of C.neo (H99). To investigate this, we assessed 
pulmonary fungal growth, CNS dissemination, and survival in mice infected 
with either H99, an SSA1-deleted H99 strain (∆ssa1), and a complement strain 
with restored SSA1 expression (∆ssa1::SSA1). Mice infected with the ∆ssa1 strain 
                                                
2 Excerpts of this chapter taken from: 
Eastman AJ, He X, Qiu Y, Davis MJ, Vedula P, Lyons DM, Park YD, Hardison SE, 
Malachowski AN, Osterholzer JJ, Wormley FL Jr, Williamson PR, Olszewski MA. 
Cryptococcal heat shock protein 70 homolog Ssa1 contributes to pulmonary 
expansion of Cryptococcus neoformans during the afferent phase of the immune 
response by promoting macrophage M2 polarization. J Immunol. 2015 Jun 
15;194(12):5999-6010. doi: 10.4049/jimmunol.1402719. Epub 2015 May 13. 
PubMed PMID: 25972480; PubMed Central PMCID: PMC4458402. 
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displayed substantial reductions in lung fungal burden during the innate phase 
(days 3 and 7) of the host response whereas less pronounced reductions were 
observed during the adaptive phase (day 14) and mouse survival increased only 
by 5 days. Surprisingly, laccase activity assays revealed that ∆ssa1 was not 
laccase-deficient, demonstrating that H99 does not require Ssa1 for laccase 
expression, which explains the CNS tropism we still observed in the Ssa1-
deficient strain. Lastly, our immunophenotyping studies showed that Ssa1 
directly promotes early M2 skewing of lung mononuclear phagocytes during the 
innate, but not the adaptive phase of the immune response. We conclude that 
Ssa1’s virulence mechanism in H99 is distinct and laccase-independent. Ssa1 
directly interferes with early macrophage polarization, limiting innate control of 
C. neo, but ultimately has no effect on cryptococcal control by adaptive 
immunity. 
Introduction 
In this chapter, we investigate the impact of cryptococcal Ssa1 on the afferent and 
efferent immune response to highly virulent C.neo strain H99. Many C.neo 
virulence factors act on the immune response directly, but few affect the early 
containment of C. neoformans, and instead promote extensive fungal growth 
during the efferent phase of the immune response that coincides with robust Th2 
polarization (49, 130). For example, the cryptococcal virulence factors urease and 
laccase promote undesirable Th2 polarization and corresponding M2 
macrophage polarization (49, 130, 196). Another group of virulence-associated 
genes including a phosphatidylinositol 4-kinase (PIK1), a ubiquitin-like protein 
(RUB1), and a cation ATPase transporter (ENA1), promote cryptococcal survival 
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in the host’s tissues and do, in fact, contribute to early fungal growth. However, 
the overall level of virulence conferred by each of these factors correlates with 
their effects on the adaptive immune response polarization and subsequent 
macrophage polarization status during the efferent phase of host response (134), 
and not highly immunomodulatory at the afferent phase.  
The mammalian heat shock protein 70 (Hsp70) functions both as intracellular 
chaperone and as an extracellular protein that can be detected by the innate 
immune system. Some pathogens express Hsp70 homologues that unfavorably 
modulate the host immune response, including Mycobacterium tuberculosis (M.tb) 
(197) and Candida albicans (C. albicans) (198, 199). These microbial Hsp70 have 
been linked to suppression of dendritic cells and induction of the non-protective 
pro-M2 cytokine IL-10. Cryptococcal Hsp70 homologue, Ssa1, is secreted as a 
component of extracellular vesicles destined for the capsule (200). Accordingly, 
Ssa1 is an immunodominant antigen for antibody production in both mice and 
humans (201-204). While microbial Hsp70 proteins show strong effects on the 
innate immune system and thus are likely to affect macrophages, cryptococcal 
Ssa1 also serves another role as a DNA-binding protein in C.neo that is a co-
activator of cryptococcal laccase expression in serotype D (serD) C.neo JEC21 
(165). However, it is unknown whether Ssa1 plays a similar role in the more 
prevalent and typically more virulent serotype A of C.neo and whether, in 
addition to its ability to regulate laccase expression, Ssa1 could interfere with the 
early control of C.neo. 
In this chapter, we study the putative C.neo virulence factor Ssa1 utilizing a 
serotype A (serA) strain of C.neo that lacks Ssa1, Δssa1 in comparison to the 
 33 
highly virulent wild-type (WT) serotype A parent strain, H99. We will first assess 
differences in the broad immune responses to H99 and Δssa1 by measuring 
pulmonary and disseminated C.neo and immunophenotyping of the infected 
lungs. We will then assess macrophage polarization during the afferent immune 
response, because HSP70 and its homologues expressed by pathogens can 
modulate macrophage activation. The sub-hypothesis for this chapter is that the 
loss of Ssa1 will result in greater ability of the afferent immune response to 
control C.neo infection, and that this will result in the development of protective 
immunity to infection with Δssa1.  
Results 
Cryptococcal Ssa1 expression contributes to pulmonary virulence of C. neoformans 
serotype A in a mouse model 
The Hsp70 homologue Ssa1 has been shown to be required for cryptococcal 
laccase expression and thus to contribute significantly to the virulence composite 
of C.neo serD strain JEC21 (165). However, the function of virulence-associated 
genes between serD and the more commonly isolated serA may differ when it 
comes to clinical impact (205, 206). In this study, we sought to determine the role 
of Ssa1 in the virulence of C.neo serA using the wildtype strain H99 and its 
mutants with targeted manipulations of the SSA1 gene: (∆ssa1) the deletant 
strain, and ∆ssa1 complemented with the functional SSA1 gene (∆ssa1∷SSA1). 
Deletant and complement strains were generated using an analogous protocol as 
described previously for serD (165). Both deletion and restoration of the SSA1 
gene were confirmed by PCR and Southern blot analysis (data not shown). The  
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Figure 2-1 Cryptococcal SSA1 gene deletion delays fungal growth in the lungs and the CNS 
dissemination, and improves survival of infected mice.  
(A) Mice were infected with 104 cells of wild type (WT) C. neoformans H99 
(serotype A), SSA1-gene deleted mutant Δssa1, or complement strain Δssa1::SSA1 
on an H99 background. Pulmonary fungal burdens were quantified on 3, 7, or 14 
days post infection (dpi). Mice infected with Δssa1 had significantly reduced 
pulmonary fungal burden relative to H99 at 3, 7, and 14 dpi and had significantly 
reduced pulmonary fungal burden relative to Δssa1::SSA1 at 3 and 7dpi.  Note 
the faster growth rates of the WT and complement strains at 0-7 dpi, and parallel 
growth rates for all 3 strains beyond day 7. Data represent pooled average CFU 
per lung or brain from separate matched experiments; n=13 mice per group per 
time point for H99 and Δssa1 and n=4 for Δssa1::SSA1. (B) Survival study was 
performed on 7-8 mice per group. Infection with Δssa1 conferred a modest but 
significant survival advantage compared to H99 and Δssa1::SSA1. (C, D) Post-
mortem CFU assay was performed on homogenized lung (C) and brain (D) from 
mice in the survival study. Pulmonary fungal burden did not differ significantly 
between any strains at the time of death, while fungal burden in the brain was 
significantly decreased in Δssa1-infected mice. († p < 0.01 relative to H99, * p < 
0.05 relative to Δssa1::SSA1, ** p < 0.01 relative to Δssa1::SSA1).  
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deletant and complement strains of H99 did not exhibit demonstrable growth 
differences from the parent strain H99 organism in vitro. Subsequently, BALB/c 
mice were infected intratracheally with 104 CFU of wild type C.neo H99, ∆ssa1, or 
Δssa1∷SSA1, and pulmonary fungal growth was assessed in the lungs at 3, 7, 
and 14 days post infection (dpi). Substantial decreases in fungal load were 
observed at 3 and 7 dpi in the lungs of mice infected with ∆ssa1 compared to 
both ∆ssa1∷SSA1- and H99-infected mice; however, beyond day 7 ∆ssa1 
acquires strong logarithmic growth rate displayed by both Ssa1-expressing 
strains (Figure 2-1A), consistent with Ssa1 expression promoting early growth of 
C.neo in the infected lungs during the afferent phase of the immune response. 
To further assess the virulence properties of the ∆ssa1 strain, we performed a 
comparative survival study in mice infected with H99, ∆ssa1 and ∆ssa1∷SSA1. 
Mice infected with H99 or ∆ssa1∷SSA1 succumbed to infection by 31 and 30 dpi, 
respectively, while mice infected with ∆ssa1 survived up to 35 dpi (Figure 2-1B). 
The median survival time for mice infected with H99 and∆ssa1∷SSA1 was 24 
and 27 days respectively. In contrast, the median survival for mice infected with 
∆ssa1 displayed a small but statistically significant extension of survival out to 
32.5 days. Interestingly, the fungal burden from the lungs at the time of death 
was not significantly different between the H99 and ∆ssa1-infected mice (Figure 






Figure 2-2 Cryptococcal SSA1 deletion suppresses laccase activity in a serotype D JEC21-Δssa1 mutant 
but not in a serotype A Δssa1 mutant.   
Laccase activity was determined by melanization of C. neoformans colonies 
cultured for 48 h in YPD media at 37°C, then plated on asparagine salts agar with 
norepinephrine, and incubated at room temperature for 5 days. Note strong 
melanin pigmentation displayed by WT serotype A strain H99, the Δssa1 mutant 
in an H99 background, and the corresponding Δssa1::SSA1 complemented 
serotype A, and the absence of pigmentation in the laccase-deficient mutant 
(Δlac) in an H99 background. Also note the pigmentation in the serotype D WT 
strain JEC21 and corresponding Δssa1::SSA1 but the minimal pigmentation 
displayed by the Δssa1 strain on JEC21 background. 
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Ssa1 expression in serotype A is not required for brain dissemination or laccase 
expression 
Since H99 is highly neurotropic, we harvested brain tissue to assess microbial 
dissemination to the central nervous system (CNS) post-mortem during the 
survival study. As expected, H99 disseminated in high titers into the brain in 
100% of the infected mice, as did the complemented strain ∆ssa1∷SSA1. 
Surprisingly, the ∆ssa1 mutant also disseminated to the brain in all the infected 
mice, albeit in reduced numbers relative to H99 (Figure 2-1D). This contrasted 
with our previously published work with the∆lac1 strains in both JEC21 and H99 
backgrounds, which consistently demonstrated that laccase-deficient C.neo did 
not disseminate into the CNS (128, 130). Thus, the current data strongly 
suggested that the ∆ssa1 strain was capable of expressing laccase.  
To test this hypothesis, we re-isolated ∆ssa1 from the brains of mice that 
succumbed to infection and tested them for completeness of the SSA1 deletion 
and for laccase activity. We found complete deletion of the SSA1 transcript by 
qPCR both in the original∆ssa1 strain used for infection and in the∆ssa1 isolated 
from the brains of mice from the survival study (data not shown), showing that 
the H99-∆ssa1 mutant did not revert to WT H99 in the infected mice. As a 
readout for laccase activity, we assessed melanin synthesis by serotype A strains 
H99, ∆ssa1, ∆ssa1∷SSA1, and ∆lac1 (Figure 2-2, top panel, left to right) and by 
the serotype D strains JEC21 WT (JEC21-WT), SSA1-deficient (JEC21-∆ssa1), and 
complement (JEC21-∆ssa1∷SSA1) (Figure 2-2, bottom panel, left to right) in 
cultures on asparagine-norepinephrine agar. In serotype A, H99, ∆ssa1, and 
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∆ssa1∷SSA1 strains displayed robust melanin pigmentation consistent with 
laccase activity, while the ∆lac1 strain lacked any pigmentation (Figure 2-2, top 
panel, left to right). In serotype D, the JEC21-WT strain displayed modest 
pigmentation, while the JEC1-∆ssa1 strain completely lacked pigmentation 
(Figure 2-2, bottom panel, middle) consistent with published studies (165), 
showing that laccase expression in JEC21 (a serD strain) requires Ssa1 while 
laccase expression in H99 (a serA strain) does not require Ssa1. Thus, apart from 
the differential role of Ssa1 in laccase regulation between strain H99 (serA) and 
JEC1 (serD), we demonstrated Ssa1’s role as a virulence factor independent of its 
role in laccase expression in the H99 strain. 
Cryptococcal Ssa1 expression accelerates but does not significantly alter the development 
of lung and brain pathologies 
Next, we sought to determine the effect of cryptococcal Ssa1 expression on lung 
pathology and the extent of the inflammatory response via histopathological 
examination of lungs from mice infected with H99 or the Δssa1 strain at 21 dpi. 
H99 and Δssa1-infected mice showed similar leukocyte accumulation in the 
alveolar spaces of lungs at 21 dpi (Figure 2-3A and B). Both strains induced 
severe lung pathology by 21 dpi, with organisms growing in widespread areas of 
the lungs. Inflammatory infiltrates were present in the infected areas, but many 
fungi resided within the alveolar space unaccompanied by inflammatory cells, 
indicating that both strains can evade the inflammatory response. We also noted 
areas of dissemination of the ∆ssa1 organisms to uninfected lung areas, 
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consistent with the somewhat delayed kinetics of fungal growth but overall 
progressive nature of pulmonary infection with ∆ssa1.    
To further establish that ∆ssa1 was capable of invading the brain and inducing 
CNS pathology, we performed histological analysis of brain sections of mice 
infected with H99 or ∆ssa1. Our data demonstrate that at the time of death, ∆ssa1 
induced CNS pathology similar to that of the H99. Both H99 and ∆ssa1 induced 
similarly-sized CNS lesions with evidence of modest inflammatory infiltrates at 
the periphery surrounding large central areas occupied mostly by C.neo and 
debris (Figure 2-3C and D).  
Cryptococcal Ssa1 expression affects pulmonary leukocyte populations during the innate 
but not the adaptive phase of the immune response in the infected lungs 
Collectively, data from our assessment of fungal burden, CNS dissemination, 
survival, and histopathology suggested that cryptococcal Ssa1 expressed by SerA 
C.neo affected the innate phase of the immune response more prominently than 
the adaptive phase. To determine the effect of Ssa1 on host defenses, we 
quantified and further characterized leukocyte populations in the lungs of mice 
infected with H99 or Δssa1 at 3, 7, and 14 dpi. Leukocytes from enzymatically-
dispersed lungs were evaluated by differential cell counts. Both H99- and Δssa1-
infected mice accumulated similar numbers of leukocytes at 3 and 14 dpi, but the 
Δssa1 strain showed slight but significant decreases of leukocyte numbers at 7 
dpi (Figure 2-4A), indicating that cryptococcal SSA1 expression may contribute 
to the magnitude of the inflammatory response at the peak of innate 
inflammation. A leukocyte subset analysis (performed by visual inspection of  
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Figure 2-3 Deletion of cryptococcal SSA1 results in delayed but similar type of lung and CNS pathology.   
Lungs and brains of mice infected with H99 (A, C, respectively) and Δssa1 (B, D, 
respectively) strains were isolated at week 3. Tissues were preserved in formalin, 
processed for histology, and cut and stained with mucicarmine to visualize C. 
neoformans. Lungs were counterstained with H&E. Representative images taken 
at 20x magnification with 100x magnification insets for lung histology images. A 
and B) Inflammatory infiltrates (black arrows) are present in both H99 and Δssa1 
strains. Note the cryptococci (red arrows, 100x) residing in the alveolar space and 
the presence of inflammatory cell infiltrates in H99- and Δssa1-infected lungs. C 
and D) Cryptococcal mucoid cysts infiltrating and displacing brain tissue. Note 
the infiltrating inflammatory cells at the periphery and cocci and cell debris in 
the middle of the cysts (blue arrows), where normal brain tissue has eroded 
(yellow arrows) in both H99 and Δssa1 strains. 
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cytospins) identified changes in frequencies of pulmonary leukocytes, 
specifically at the early time points. Relative to H99 infected mice, the Δssa1-
infected lungs accumulated a higher proportion of mononuclear phagocytes 
(Figure 2-4B) and a much lesser proportion of granulocytes (eosinophils and 
neutrophils) (Figure 2-4C-D), indicating that cryptococcal Ssa1 contributed to the 
development of innate inflammation, especially its granulocytic component. In 
contrast, no changes in magnitude or frequency of pulmonary leukocyte subsets 
were observed on day 14, providing a clue that the adaptive response did not 
significantly differ between the H99- and Δssa1-infected mice. Thus, deletion of 
cryptococcal gene SSA1 altered the composition of lung leukocyte populations 
during the innate but not adaptive phase of the immune response. 
Cryptococcal Ssa1 promotes M2 macrophage polarization during the innate but not 
adaptive phase of the immune response to cryptococcal infection 
Pulmonary control of C.neo depends on macrophage polarization status: M1 
(classical activation) is protective and M2 (alternative activation) is non-
protective. Thus, we next sought to determine whether the early Ssa1-induced 
impairment in pulmonary fungal clearance was linked to differential M1/M2 
polarization. First, we assessed early M1/M2 macrophage polarization markers 
in H99 and Δssa1-infected lungs using immunohistochemistry. Due to low levels 
of inflammation during the first days of infection (unpublished observations), 
lung sections were analyzed at 8 dpi, a time point that still largely represents an 
innate/afferent phase of the immune response. In lung sections obtained from 
mice infected with H99, we observed clusters of cells highly expressing Arg1 and 
mannose receptor (CD206), but very few cells positive for inducible nitric oxide  
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Figure 2-4 Deletion of cryptococcal SSA1 resulted in a 
similar magnitude but distinct polarization of early but 
not late inflammatory responses in the infected lungs.   
Lung leukocytes were isolated and 
characterized by microscopy at 3, 7, and 14 
dpi from C. neoformans-infected lungs. Total 
leukocyte numbers in the lungs were 
equivalent in H99 versus ∆ssa1-infected 
lungs with the exception of a small but 
significant decrease on day 7 in the Δssa1-
infected lungs (A). Monocytes (B), 
eosinophils (C), neutrophils (D) and 
lymphocytes (E) were identified by 
morphology and staining characteristics. 
Monocyte frequency was significantly 
increased at 3 and 7 dpi in Δssa1-infected 
mice, while eosinophil and neutrophil 
frequency was significantly decreased at 7 
dpi in ∆ssa1-infected mice relative to H99-
infected mice, and lymphocyte frequency 
never differed significantly between the two 
strains at any time points. N=5-11 mice per 
time point per strain, representing 3 separate 




synthase (iNOS) (Figure 2-5), consistent with presence of M2 macrophages in the 
H99-infected lungs. In contrast, we observed fewer CD206 and Arg1-positve cells 
and higher number of cells expressing iNOS in lung sections obtained from mice 
infected with Δssa1, suggesting more predominant M1 polarization in the 
absence of cryptococcal Ssa1.  
To evaluate these differences more quantitatively and to evaluate the M1/M2 
status of pulmonary mononuclear phagocytes at the earlier and later time points, 
we next performed flow cytometry analysis on leukocytes populations obtained 
from H99- and Δssa1-infected lungs at 3 and 14 dpi. We measured expression of 
MHC class II (high expression consistent with M1 polarization) and CD206 and 
Galectin 3 (high expression consistent with M2 polarization) on CD11c+ 
populations of lung leukocytes which, following exclusion of T cells, B cells, 
neutrophils, and eosinophils (Figure 2-6A, also see Materials and Methods) (41, 
44, 92) are highly enriched for resident alveolar macrophages as well as 
monocyte-derived exudate macrophages and dendritic cells.  These cell subsets 
represent fully differentiated mononuclear phagocytes, which are all capable of 
M1/M2-type polarization as well as killing of C.neo. Results showed significant 
differences in the expression levels of all of these markers by CD11c+ myeloid 
cells between H99 and Δssa1-infected lungs at 3 dpi. Surface expression of MHC 
class II (MHC II) was increased (Figure 2-6B) while surface expression of CD206 
and Galectin 3 (Gal3) was decreased (Figure 2-6 C-D) at 3 dpi in Δssa1-infected 
lungs compared to those infected with H99, consistent with enhanced M1 
polarization in Δssa1-infected lungs and more pronounced M2 polarization in  
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Figure 2-5 Cryptococcal SSA1 expression promotes the induction of crucial M2 proteins ARG1 and 
CD206 while preventing induction of M1 protein iNOS in the lungs.   
Defrosted lung sections taken at 8 dpi were stained with DAPI (blue) to show 
nuclei, and antibodies for M1 activation marker iNOS (left panel), M2 activation 
marker Arginase (Arg1, middle panel) and M2 activation marker mannose 
receptor (CD206, right panel). Secondary FITC conjugated antibodies (green) 
were used to visualize immunoreactive proteins. Note the significant induction 
of Arg1 and CD206 and the absence of iNOS staining in H99-infected lung 
sections. In contrast, iNOS protein can be detected in ∆ssa1-infected sections, 
while the M2 markers Arg1 and CD206 show strikingly less immunoreactivity in 




Figure 2-6 Cryptococcal Ssa1 increases surface expression of M2 activation markers and decreases surface 
expression of MHCII during the innate but not adaptive phase of the immune response in the infected 
lungs.   
Flow cytometric analysis of leukocyte populations from infected mouse lungs 
used the gating scheme in (A) to sequentially gate out debris, non-immune cells, 
lymphocytes, and granulocytes and then we selected the CD11c+ subset of this 
population. M1 activation marker MHC class II (B) and M2 activation markers 
Gal3 (C) and CD206 (D) surface expression was assessed at 3 and 14 dpi. Note 
the significant increase in MHCII and decrease in CD206 and Gal3 surface 
staining in Δssa1-infected mice at 3 dpi, but a resolution of these differences by 
14 dpi. Representative histograms were selected from two separate, matched 
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experiments. N = 5 per treatment per time point. Combined mean fluorescence 
intensity plots represent high-expressing cells (MHC II) or positively staining 




H99-infected lungs on 8 dpi. In contrast, the surface expression levels of these 
markers in H99 and Δssa1-infected groups were equivalent at 14 dpi (Figure 
2-6B-D), demonstrating similar M1/M2 polarization profiles of these 
mononuclear cells during the adaptive phase of the immune response in the 
presence and absence of cryptococcal Ssa1.   
To further assess and verify our findings, additional M1/M2 markers and 
M1/M2-associated cytokines were analyzed by quantifying mRNA expression in 
adherence-purified macrophages from lungs of mice at 3 and 14 dpi with H99 
and ∆ssa1. At 3 dpi, macrophages from ∆ssa1-infected lungs induced 
significantly more transcript for M1 activation gene iNOS (Figure 2-7A) and less 
transcript for M2 activation genes Arg1 (Figure 2-7B), Gal3 (Figure 2-7D), CD206 
(Figure 2-7E) and FIZZ (not shown) at 3 dpi than did those infected with H99. 
Further, the iNOS:Arg expression ratio was M1-skewed, with ∆ssa1-infected lung 
macrophages having a higher expression ratio, compared to a lower expression 
ratio (indicating a less M1- and more M2-polarized phenotype) in the H99-
infected lung macrophages. Consistent with our flow cytometry readouts, at 14 
dpi none of these genes were differentially expressed, nor were gene expression 
ratios differentially skewed between H99 and Δssa1- infected groups. 
Collectively, these data indicate that cryptococcal SSA1 expression by SerA 
promotes M2 polarization during the innate, but not the adaptive, phase of the 




Figure 2-7 Cryptococcal Ssa1 increases induction of 
macrophage M2 activation markers and decreases 
induction of M1 activation marker iNOS during the 
early but not the late phase of lung infection in mice.   
Macrophages were isolated from infected 
mouse lung leukocyte preparations by 
adherence selection. iNOS (A), Arg1 (B), 
the iNOS/Arg1 expression ratio (C), 
CD206 (D) and Gal3 (E) mRNA transcript 
levels were assessed by qPCR. Note the 
increase in iNOS in ∆ssa1-infected mouse 
macrophages relative to H99-infected 
mouse macrophages at day 3 but not at 
day 14. Arg1 is not significantly different 
between the macrophages at day 3. 
However, a paired iNOS/Arg1 ratio (C) 
where an individual mouse’s 
macrophage iNOS mRNA fold change 
was divided by its own Arg1 mRNA fold 
change yielded highly significant M1-
skewed signature in macrophages from 
∆ssa-infected mice but a far lower ratio in 
H99-infected mouse macrophages at day 
3, but not at day 14, where both ∆ssa1- 
and H99-infected mice had M2-skewed 
macrophages. Also note the decrease in 
expression of both M2 activation markers 
CD206 and Gal3 in Δssa1- infected mice 
relative to H99-infected mice at day 3, but 
not at day 14. N = 8 from 2 separate 
experiments. * p < 0.05, ** p < 0.01 using 
Student’s t-test.  
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Cryptococcal SSA1 expression modulates innate but not adaptive phase pulmonary type 
2 cytokine responses in infected lungs 
We next investigated the cytokine mRNA expression levels by leukocytes 
obtained from the lungs of H99- and Δssa1-infected mice. Cryptococcal SSA1 
deletion resulted in decreased expression of non-protective Th2 cytokines IL-4 
and IL13 at day 3 but not day 14 (Figure 2-8A and B), indicating that cryptococcal 
Ssa1 acted as an early inducer of type 2 cytokine production. The expression of 
protective Th1-driving IFNγ was not significantly different between the groups 
(Figure 2-8C). However, the IL-4:IFNγ ratio, shown to be a good indicator of type 
1 versus type 2 response balance, was decreased in the absence of Ssa1 at 3 dpi 
(Figure 2-8D), demonstrating that the early cytokine balance of type 1/type 2 
cytokines was shifted towards type 2 in the presence of cryptococcal Ssa1. 
Consistent with the similar outcomes of lung pathology and leukocyte 
populations at the later time point, we did not observe differences in Th1/Th2 
polarizing cytokine expression by leukocytes from H99 versus Δssa1-infected 
lungs on day 14 (Figure 2-8A-D). Thus, cryptococcal Ssa1 expression modulates 
innate but not adaptive phase pulmonary type 2 cytokine responses in the 
infected lung. 
Cryptococcal SSA1 expression promotes alternative activation markers and down-
regulates classical activation markers during C. neoformans-macrophage interaction in 
vitro 
To determine if SSA1 expression is sufficient to directly promote M2 polarization 
of macrophages, we assessed the M1/M2 polarization response of bone marrow- 
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Figure 2-8 Cryptococcal SSA1 expression results in 
increased pro-Th2 cytokine induction and increased 
IL4:IFNγ regulation ratio in pulmonary leukocytes 
from infected mice during innate phase of the 
immune response to C. neoformans. 
Leukocyte preparations from H99 and 
Δssa1- infected mouse lungs were 
processed for mRNA quantification of 
IL-13 (A), IL-4 (B), IFNγ (C) and for the 
IL-4:IFNγ induction ratio (D) at 3 and 14 
dpi. Note the decrease in non-protective 
cytokines IL-4 and IL-13, along with the 
decreased IL-4:IFNγ induction ratio in 
the leukocytes obtained from ∆ssa1-
infected mice relative to the H99-infected 
mice at day 3, followed by progressive 
but no longer differential cytokine 
induction in the lungs of ∆ssa1- and H99-
infected mice on day 14. N = 5/time 
point/group from 2 separate 




derived macrophages (BMM) following direct stimulation with C.neo H99 or 
∆ssa1 in vitro. BMMs were harvested after stimulation with H99 or ∆ssa1 for 24h 
and analyzed for expression of M1 and M2-associated genes by qPCR. 
Expression of M1 activation marker iNOS was increased, while expression of M2 
activation markers Gal3 and CD206 (Figure 2-9B) as well as Fizz1 (data not 
shown) was decreased in macrophages stimulated with Δssa1 compared to those 
stimulated with H99 (Figure 2-9) as early as 24h post-treatment. Further, the 
iNOS:Arg expression ratio, a broadly accepted readout of M1/M2 polarization 
balance, was heavily skewed towards M1 in the ∆ssa1-treated macrophages 
compared to those stimulated with H99. Thus, these findings demonstrate that 
cryptococcal Ssa1 directly promotes M2 polarization in vitro.   
Despite the ability of Ssa1 to directly modulate macrophage polarization, the 
virulence factor on its own does not significantly affect the efferent immune 
response that eventually develops. The efferent response is reliant on DCs as the 
antigen presenting cells that traffic to the lymph node and prime T cells. In order 
to reconcile our findings of Ssa1-induced M2 polarization with the few observed 
changes in the adaptive immune response to ∆ssa1, we assessed the activation of 
DCs during infection with H99 versus ∆ssa1. Using the same markers of M1/M2 
polarization as in Figure 2-6— MHCII, CD206, and Gal3 surface expression— we 
found no significant differences in CD11b+/CD11c+ DC polarization at 3 or 14 
dpi between H99 and ∆ssa1-infected mice (Figure 2-10), which is in contrast to 
the Ssa1-induced changes in macrophage polarization at 3 dpi detailed in Figure 
2-6. Furthermore, while lung leukocyte culture supernatants yielded early 
Th1/Th2 polarization differences, there were no differences in TNFα levels at the  
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Figure 2-9 In vitro stimulation with an SSA1-expressing cryptococcus is sufficient to decrease M1 and 
increase M2 activation markers in bone marrow derived macrophages.   
mRNA was extracted from bone marrow-derived macrophages stimulated with 
live H99 or ∆ssa1 C.neo for 24 hours and qPCR was performed for M1 activation 
marker iNOS (A) and M2 activation markers Arg1 (A), CD206 (B) and Gal3 (B). 
iNOS/Arg1 expression ratio (A) was also prepared. Note the increase in iNOS 
expression and iNOS/Arg1 ratio and the decreases in Arg1, CD206, and Gal3 
expression in the Δssa1-infected macrophages relative to the H99-infected 
macrophages. N=6-9 from three separate experiments. * p < 0.05, ** p < 0.01 
using Student’s t-test.  
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Figure 2-10 Ssa1 does not affect 
dendritic cell polarization in vivo at 
early or late times post-infection. 
Dendritic cells were sorted 
from myeloid cells via 
expression via CD11b 
expression. This specific DC 
subset was then analyzed by 
flow cytometry for 
expression of DC1 marker 
MHCII (A) and DC2 markers 
CD206 (B) and Gal3 (C) at 3 
and 14 dpi. There were no 
significant differences in 
surface expression observed 
in any of these parameters. N 
= 10 from two separate, 
matched experiments. 
Statistical analysis was 





Figure 2-11 Ssa1 deletion does not alter TNFα  secretion by lung leukocytes early during infection. 
Lung leukocytes were isolated from enzymatically-digested lungs, plated, and 
cultured to assess production of TNFα by RT-qPCR (A) and ELISA (B). TNFα 
production was modestly increased in Δssa1-infected mice at 14 dpi at the 
protein level, but not at the transcriptional level. N = 10 from two separate, 
matched experiments. Statistical analysis was performed by 2-way ANOVA and 
student’s t-test.  
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mRNA or protein levels at 3 dpi (Figure 2-11). Thus, Ssa1-mediated effects on 
antigen presenting cells do not extend to DCs— the cell type responsible for 
priming of T cell responses— or to early TNFα production within the lung 
environment, both of which are implicated in the development of protective 
immunity. 
Discussion 
Here, we demonstrate that the cryptococcal Hsp70 homologue Ssa1 plays a 
unique role as a virulence factor that interferes with the innate immune response 
by promoting early M2 activation of pulmonary macrophages, thereby 
interfering with the first line of defense against cryptococcal infection. This is the 
first demonstration of a cryptococcal (fungal) virulence factor that works in this 
fashion (i.e. that significantly modulates innate host defenses, while leaving the 
development of the adaptive immunity intact). Our studies also reveal that in 
contrast with previously known functions of Ssa1 in C.neo serotype D, Ssa1 does 
not regulate cryptococcal laccase expression in strain H99 (serotype A strain). 
This finding of differential regulation of cryptococcal virulence components 
between strains of serotypes A and D provides evidence that the divergence 
between these strains stretches well beyond initially-noted differences in these 
serotypes’ capsular composition. As a whole, this work significantly advances 
our understanding of cryptococcal factors’ interactions with the mechanisms of 
host defenses in the infected host. 
Our studies identified Ssa1 as a cryptococcal factor that promotes early 
alternative activation of pulmonary macrophages and other CD11c+ 
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mononuclear phagocytes during the innate phase of the immune response to 
cryptococcal infection. This conclusion is based on the following observations 
obtained by infecting mice with Ssa1-deficient SerA C.neo (relative to mice 
infected with WT H99): 1) a significant early reduction in pulmonary fungal 
burden; 2) repression of alternative activation-associated genes and surface 
expression of M2 markers by macrophages and the entire population of CD11c+ 
mononuclear cells; 3) increased abundance of iNOS protein expression and 
MHCIIhi cells in the lungs during the innate phase of the immune response. The 
subsequent in vitro data show that deletion of cryptococcal SSA1 resulted in 
down-regulation of M2 markers and up-regulation of M1 markers when bone 
marrow derived macrophages were stimulated with C.neo ∆ssa1 versus H99. 
These data indicate that cryptococcal Ssa1 in serotype A strain H99 directly 
affects macrophage polarization pathways, promoting M2 and suppressing M1 
pathways in infected macrophages. To our knowledge, this is the first 
cryptococcal factor known to affect macrophage polarization this early during 
the infection and in such a direct fashion. 
The unique timing of the effects that Ssa1 induces in the host sets it apart from 
other virulence factors studied in similar systems (49, 128, 130, 161, 196). 
Observed differences in macrophage polarization state in the presence and 
absence of Ssa1 during C.neo infection (expression of M2 markers CD206, Arg1, 
and Gal3 and M1 markers iNOS and MHC class II at both the mRNA and the 
protein level) were significant on days 3 and 7 post-infection. However, by day 
14 these differences in macrophage polarization in H99-WT and H99- ∆ssa1 
infected lungs resolved completely (Figures 6, 7, and 8), consistent with the 
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similar phenotypes of the adaptive immune response polarization (Fig. 5). 
Consequently, the fungal growth rate in the lungs is not inhibited beyond the 
early time points and we observe only a temporary delay in pulmonary fungal 
burdens, CNS dissemination, and infected mouse mortality in the absence of 
cryptococcal SSA1 expression. Together, these data demonstrate that Ssa1 is a 
virulence factor that selectively interferes with the innate immune response 
without significant effects on generation of the adaptive immune response.  
This mechanism of the immunomodulatory effects of Ssa1 contrasts with 
previously reported effects of other virulence factors that modulate the immune 
responses. These factors, such as urease (49, 161, 196), phospholipase (128, 207), 
and laccase (130) promote the development of non-protective Th2 immunity and 
subsequent M2 polarization and confer a fungal growth advantage late during 
the infection. It is also in contrast with other factors, such as PIK1, RUB1, ENA1 
(134), and VAD1 (132), which confer growth advantages during both the innate 
and adaptive phase of the immune response but nevertheless predominantly 
modulate the cytokine environment during the efferent phase of the immune 
response in C.neo -infected lungs. In contrast, Ssa1 directly modulates 
macrophage- C.neo interactions only during the innate phase, with little to no 
effect on the development of adaptive immunity. In an attempt to specifically 
address the mechanism of Ssa1-dependent effects on macrophages, our 
laboratory has performed studies using mice deficient in the SRA receptor, 
which we originally thought to be the major receptor for the Ssa1 protein (121). 
Through our investigation, we have found that it is possible that some effects of 
Ssa1 on macrophages could be induced by SRA; however, the data were not very 
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clear, hinting that multiple receptors and signaling pathways were likely to be 
involved. 
Our novel findings regarding the virulence effects of cryptococcal Ssa1 also have 
other important implications for understanding cryptococcal interactions with 
the host’s immune system. First, significant modulation of the innate immune 
response and early fungal load by a virulence factor is not always sufficient to 
induce downstream changes in the phenotype of the adaptive immune response. 
Second, our findings show that the direct effect of a virulence factor on 
macrophage polarization can eventually be overcome by the extrinsic effects of 
cytokines induced by the cells of the adaptive immune system. Potential 
mechanisms for this counter-intuitive finding could include a) contribution of 
other virulence factors that do not affect innate control but are known to skew 
the adaptive immune response, such as laccase and urease (49, 129, 130, 165), 
which are expressed by Δssa1, or b) possible differential effects of Ssa1 on 
dendritic cells, responsible for priming and perpetuating the adaptive response. 
Together, these data further support our view that cytokine environment 
manipulation could be a promising therapeutic strategy that may override many 
aspects of cryptococcal virulence and host deficiencies leading to improper 
M1/M2 polarization status within the infected host. 
The present study also highlights a critical difference in Ssa1’s contribution to the 
virulence composite between two strains that belong to serA and serD, which is 
linked to their differential regulation of cryptococcal laccase expression. We 
initiated our work based on an assumption that SSA1 deletion in H99 would 
deprive the fungus of virulence properties associated directly with Ssa1 as well 
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as the virulence properties of laccase. This was based on studies in C.neo JEC21 
(serD), which demonstrated that Ssa1 is required for laccase expression (165). 
Laccase is an enzyme required for melanin production in C.neo (162-164) and a 
virulence factor essential for cryptococcal CNS colonization (128, 130). 
Accordingly, the ∆ssa1 strain on a JEC21 background showed a profound 
suppression of melanin production and a profound defect in CNS invasion (165). 
The SSA1 deletion in strain H99 did not reproduce these effects, as H99-∆ssa1 
successfully disseminated from lungs into the CNS, induced CNS pathology, and 
expressed comparable melanin pigmentation to the parent H99 strain (Figure 2-1, 
Figure 2-2, Figure 2-3). Likewise, SSA1 deletion in H99 did not induce the 
immunological consequences of laccase deletion, which were predominantly 
observed during the efferent phase of the immune response (130). These 
differences in the regulation of laccase expression between H99 (serA strain) and 
JEC21 (serD strain) allowed us to define a laccase-independent role of Ssa1 as a 
standalone virulence factor and also elucidated a novel and crucial difference in 
virulence gene regulation between C.neo strains. In addition to previously-
observed differences in regulation of cryptococcal cytochrome c oxidase subunit 
1 (COX1) (205), our data underscores major differences in gene regulation among 
C.neo strains. While it is yet unknown how this impacts the spectra of host 
susceptibilities and pathogenicity of serotypes A and D, our studies provide 
evidence of differential regulation of crucial virulence-associated genes between 
representative strains of these serotypes. If the observed differences in virulence 
gene regulation between strains H99 (serA) and JEC21 (serD) proved to be 
consistent between all or most serotype A and D strains, our findings would help 
to explain differential epidemiology between serotypes, similarly to what has 
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been found for two cryptococcal species- C.neo and C. gatti- in recent studies (24, 
208).  
Finally, while our studies focused on C.neo, we believe they have broader 
implications for host interactions with pathogen-derived Hsp70. Other 
pathogens have been shown to employ Hsp70 as virulence factor/modulator of 
innate responses including M.tb (197, 209), Toxoplasma gondi (210, 211) and 
Candida sp. (198). While the mechanism of the Ssa1-induced effects on the host 
and on pathogen’s virulence appear to be different in each group of pathogens, 
these previously published studies combined with our present work support the 
broader importance of Hsp70 family proteins as standalone virulence factors and 
immune response modulators.  
In this chapter, we showed that Ssa1 could modulate macrophage polarization, 
but had no effect on DCs or on certain key afferent-phase cytokines, such as TNF
α. We hypothesize that Ssa1 ultimately had no effect on the efferent response 
because it failed to modulate DC activation, which is the cell type primarily 
responsible for priming and restimulating CD4 T cells in the lymph node and the 
lungs (9, 40, 49). In other models, classically activated DCs (DC1) prime 
Th1/Th17 responses, which, in C.neo, are protective responses. It is unclear why 
Ssa1 can modulate afferent-phase macrophages but not afferent-phase dendritic 
cells, but this may be due to possible differential receptor expression between 
DCs and macrophages (such as SRA), or the well-characterized ability of DCs to 
phagocytose and kill C.neo more effectively than macrophages, which could 
effectively inactivate the cryptococcal Ssa1 before it can successfully signal and 
modulate phagocyte activation. Because DCs are responsible for activating CD4 
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T cells during C.neo infection, the next chapters will focus more exclusively on 
DC activation. 
In summary, our findings provide novel insights regarding the 
immunomodulatory role of cryptococcal Ssa1 and we identify important gene 
regulation differences between serotypes A and D. We have shown that Ssa1 
promotes early M2 macrophage polarization and that this form of immune 
modulation improves fungal growth during the innate phase of the immune 
response. Yet our data also emphasizes that the immunophenotype of the 
adaptive immune response ultimately defines the outcome of infection. 
Furthermore, our studies reveal that immune modulation and the propensity for 
CNS dissemination mediated by Ssa1 may vary between serotypes and depends 
on whether or not laccase expression is induced.  
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Chapter 3 TNFα is required for generation of lasting DC1 
phenotype throughout Cryptococcus neoformans 
pulmonary infection3 
Abstract 
A Th1/Th17 response is required to clear Cryptococcus neoformans (C.neo), a 
fungal pathogen infecting immunocompromised patients, including those on 
anti-TNFα antibody (αTNFα) therapy. To determine the mechanisms by which 
early TNFα signaling promotes the generation and stability of a protective 
Th1/Th17 response, CBA/J mice received a single dose of αTNFα or isotype 
control antibody followed by infection with C.neo 24067. We found that the 
robust Th1/Th17 responses in control mice were replaced by non-protective 
responses with many Th2 features and fluctuating cytokine levels in the αTNFα-
treated and infected group, in which the DC1 signature in CD11c+ cells was 
suppressed through 28 days of infection. We modeled the effects of TNFα on DC 
phenotypes in vitro using bone marrow-derived DCs stimulated with IFNγ with 
or without TNFα, then challenged with IL-4 to assess plasticity of DC1 and DC2 
                                                
3 Excerpts of this chapter taken from: 
Eastman, A.J., J. Xu, N. Potchen, A. denDekker, L. M. Neal, G. Zhou, A. 
Malachowski, S. Kunkel, J. J. Osterholzer, and M. A. Olszewski. TNFα is 
necessary for long lasting protective immunity to fungal infection through 
epigenetic stabilization of classically activated dendritic cells and bone marrow 
dendritic cell precursors. In submission at Science Immunology. 
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markers at the mRNA and protein level. DCs were plastic to their cytokine 
environments, as assessed by the expression of iNOS, Fizz1, MHCII, CD206, IL-
12b, and IL-13, but the addition of TNFα reduced the plasticity. This TNFα-
mediated training was observed in the presence of antigen as well, and 
correlated to our in vivo findings. Using TNFα receptor 1 and 2 inhibitors in vitro, 
we found that this training is dependent on both TNFR1 and TNFR2 in an 
additive manner. We conclude that TNFα is necessary to train DCs during C.neo 
infection, thus resulting in priming and perpetuation of protective Th1/Th17 
immunity, and that in the absence of TNFα, this training does not occur, 
resulting in a non-protective Th2 immune response. 
Introduction 
In the previous chapter, we found that despite early modulation of host 
macrophage polarization, the presence or absence of cryptococcal Ssa1 does not 
impact the phenotype of the efferent immune response to C.neo. DCs– and not 
macrophages– are thought to be the primary drivers of the developing adaptive 
immune response to C.neo (9, 40, 49), and Ssa1 did not modulate DC activation or 
polarization, as shown in Figure 2-10. Further, the pulmonary expression of a 
major DC function mediator, TNFα, was unchanged by expression of Ssa1. 
Thus, we next proceed to a different model of afferent immune modulation 
during C.neo infection where afferent-phase TNFα is depleted (but, importantly, 
recovers during the late afferent-early efferent phase) and results in 
nonprotective efferent immune responses. Neither a) the full immunophenotype, 
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nor b) the mechanism behind long-term immune modulation, resulting from 
transient TNFα depletion is known. 
The necessity for TNFα early during cryptococcal infection has been well 
documented (45, 81, 84, 85, 88). CBA/J mice, which normally clear C.neo from the 
lungs within 4 weeks and limit extrapulmonary dissemination, have a persistent 
and/or progressive infection when TNFα has been depleted by a single injection 
of TNFα blocking antibody at the time of infection (45, 84, 85). C57BL/6 mice, 
which are normally unable to clear C.neo from the lungs and have a persistent 
infection, are able to clear C.neo when co-infected with an adenoviral vector 
expressing TNFα (174). Immunocompromised patients with cryptococcosis that 
produce less TNFα tend to succumb to C.neo infection earlier than those that can 
mount a robust TNFα response (81). Patients receiving anti-TNFα monoclonal 
antibody therapy for autoimmune disorders are also at increased risk for 
cryptococcosis (28-30); they are also more susceptible to other infectious agents 
such as Histoplasma capsulatum and Mycobacterium tuberculosis (27, 31). The 
mechanism underlying patients’ increased susceptibility to these infections is 
unclear, but studies by Herring et all. (84) and Milam et al. (174) of TNFα linked 
early TNFα expression with DC activation. Furthermore, a particular strain of 
Cryptococcus capable of suppressing host TNFα, causes outbreaks in the Pacific 
Northwest of the United States in humans without known underlying 
immunological defects (88). The precise mechanism behind the necessity for 
TNFα in generating protective immunity is unknown. 
DCs are responsible for priming the immune response to C.neo in the lymph 
nodes, and also for re-stimulating antigen-specific T cells in the lungs (reviewed 
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in (212)). Upon maturation, DCs begin to present more antigen via MHC class II 
(MHCII), upregulate co-stimulatory molecule expression, downregulate surface 
expression of many phagocytic receptors, upregulate CCR7, and traffic to local 
lymph nodes (38, 44, 213). DCs can be classically activated (DC1, characterized 
by high expression of iNOS, IL-12, MHCII, and costimulatory molecules) 
wherein they prime Th1/Th17 responses, or alternatively activated (DC2, 
characterized by high expression of arginase, Fizz1, Gal3, IL-13, and CD206), 
wherein they prime Th2 responses (reviewed in (213)). DC1 activation has been 
proposed as a mechanism behind protective immunity to C.neo (84), but has not 
been conclusively shown in the lungs. 
There are two canonical receptors for TNFα, TNFα receptor 1 (TNFR1) and TNF
α receptor 2 (TNFR2). Both TNFRs can be expressed on the same cell at various 
stages of immune cell development and are capable of crosstalk (214), although 
TNFR1 tends to predominate in circulating human peripheral blood monocytes 
(215). However, both receptors are capable of signaling through NFκB and the 
MAPK pathways. In other models, such as during oral Salmonella infection, DC 
maturation is dependent upon TNFR1 (216); further, a more recent study ties DC 
maturation to TNFR1 as well, but prolonged DC survival to both receptors (217). 
While much is known about the necessity for TNFα signaling during C.neo 
infection, the dominant TNFR, if any, remains unknown.  
In this chapter, we assess the cellular mechanism behind the requirement for 
TNFα during the afferent immune response to C.neo infection. We begin by 
carefully immunophenotyping CD4 T cells during the efferent response, 
followed by assessing the activation and polarization of the DC subsets in the 
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lungs, which are responsible for priming and restimulating T cells during C.neo 
infection. We then model the activation and polarization of DCs in vitro in the 
presence or absence of TNFα and known DC polarization-skewing cytokine 
factors, and determine which TNFR is necessary for generation of long-term 
protective immune responses. The subhypothesis for this chapter is that transient 
TNFα depletion interferes with DC-mediated activation of T cell-mediated 
immunity during C.neo infection, in a TNFR2-mediated manner. 
Results 
TNFα signaling promotes stability of Th1 polarization during pulmonary C.neo 
infection 
To dissect the mechanisms by which early TNFα signaling affects host defenses 
to C. neoformans, isotype antibody-treated and anti-TNFα antibody-treated 
CBA/J mice were infected intratracheally with a clinical isolate of C. neo (the low 
pathogenic strain 52D, which allows for prolonged analysis of immune responses 
in the host). First, we determined pulmonary fungal burdens and measured 
fungal dissemination by evaluating spleen CFU. Consistent with published 
work, we found that transient depletion of TNFα prevented fungal clearance at 
14 and 28 days post-infection (dpi) resulting in a 3-log increase in fungal load by 
28 dpi (Figure 3-1A). C.neo disseminated to the spleen in each treatment group, 
but the dissemination in control mice was minimal and transient; without TNFα, 
C.neo disseminated to the spleen in a progressive manner through 28 dpi (Figure 
3-1B). We confirmed that TNFα levels begin to recover in TNFα-depleted mice 
after 7 dpi (Figure 3-1E), thus demonstrating that single dose of anti-TNFα 
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treatment at the time of infection yielded lasting dysfunction in pulmonary and 
systemic control of C.neo infection. 
 
Figure 3-1 Afferent phase TNFα yields protective Th1/Th17 responses throughout infection. 
 (A and B) Pulmonary fungal burden (A) and splenic fungal burden (B) were 
evaluated at 3, 7, 14, and 28 days post-infection (dpi). N = 26-32 from five 
separate, matched experiments. (C and D) Lung leukocytes recovered after 
enzymatic lung digest were enumerated by light microscopy (C), cytospun onto 
slides, diff-quick stained, and lymphocytes counted (D). N = 26-32 from five 
separate, matched experiments. Statistical analysis was performed using 
student’s t-test or ANOVA as appropriate. Non-parametric data was log-
transformed. *p< 0.05; **p<0.01; ***p<0.001. (E) Cytometric bead array for TNFα 
was performed on serum from whole blood of infected mice. N = 36-48 from 3-4 
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separate, matched experiments. Nonparametric data was log transformed and 
two way ANOVA and student’s t-test were performed. * p < 0.05; *** p < 0.001; ‡ 
statistically significant difference between TNFα serum levels in Anti-TNFα mice 
at 14 dpi compared to 7 dpi.  
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We next evaluated the effect of early TNFα signaling on magnitude of cellular 
response in the infected lungs. We observed that leukocyte recruitment at 14 and 
28 dpi was diminished in anti-TNFα-treated mice (Figure 3-1C), indicating that 
early TNFα signaling has a lasting effect on magnitude of inflammatory 
response. There was small but statistically significant increase in the frequency of 
lymphocytes in TNFα-depleted mice at 14 dpi, but no other differences in 
frequencies of leukocyte subsets in the infected lungs throughout 28-days of 
infection (Figure 3-1D), suggesting that the decrease in pulmonary leukocyte 
accumulation in TNFα-depleted mice was not restricted to a specific subset. 
Since CD4+ T cells are required for proper protective immunity to C.neo, we 
assessed the proportion of CD4+ T cells in the lung leukocyte populations by 
flow cytometry. TNFα-depleted mice had a reduced proportion of CD4+ T cells 
within their total leukocyte population at 14 and 28 dpi (Figure 3-2A). We next 
assessed CD4+ T cell activation and found fewer cells expressing CD44 and more 
cells expressing CD62L in TNFα-depleted mice relative to control mice at 14 and 
28 dpi, implying that CD4+ T cells from TNFα-depleted mice were less activated 
(Figure 3-2B). Thus, early TNFα signaling was required for optimal recruitment 
of pulmonary leukocytes, including CD4+ T cells with an activated effector 
phenotype. 
To further evaluate the effect of early TNFα signaling on CD4+ T cell polarization, 
we first measured cytokine expression by CD4+ T cells via intracellular flow 
cytometry. We found that CD4+ T cells from TNFα-depleted mice made less of 
the protective cytokines IFNγ and IL-17 and more of the non-protective IL-13 at  
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Figure 3-2 TNFα  is required for CD4 T cell recruitment and activation. 
CD4 T cells were identified by flow cytometry by sequentially gating live 
cells/CD45+/CD3+/CD8-/CD4+. The frequency of CD4 T cells (A) and their 
activation state (B) was determined by CD62L and CD44 surface staining. N = 8 
from two separate, matched experiments. Representative histogram overlays are 
presented with bar graphs representing average percent positive. Statistical 




14 dpi as assessed by intracellular flow cytometry (Figure 3-3). Interestingly, 
despite a largely Th2 biased polarization, more CD4+ T cells from TNFα-depleted 
mice made TNFα than did in the control mice. These data provided evidence that 
early TNFα signaling is required for optimal Th1 polarization of CD4+ T cells 
and its depletion alters the Th1/Th2 balance of T cells recruited to C. neo-infected 
lungs.  
We next broadly assessed the transcriptional profile of CD4+ T cells isolated from 
dispersed lungs by MACS via qPCR arrays, which revealed that CD4+ T cells 
from TNFα-depleted mice showed strong upregulation of Th2 transcription 
factors and Th2-related genes and lower amounts of Th1 transcription factors 
and related genes than control mice at all time points post-infection (Figure 
3-4A). Thus, early TNFα is necessary for protective CD4+ T cell-mediated 
immunity to C.neo.  
TNFα is required for DC1 polarization in vivo 
Because polarization of lung CD4+ T cells following transient TNFα depletion 
was dysregulated, we next assessed the number, maturation, and polarization of 
DCs in the lungs. There was a small but statistically significant decrease in 
frequency of total monocytes in TNFα-depleted mice occurring at 14 dpi (Figure 
3-5A). Due to the differences in total leukocyte numbers (Figure 3-1C), there 
were significant decreases in the number of monocytes in the lungs of TNFα-
depleted, infected mice at 14 and 28 dpi (Figure 3-5B). To broadly characterize 
the polarization of differentiated lung DCs, we isolated RNA from CD11c+ cells  
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Figure 3-3 TNFα  results in Th1/Th17 polarization of CD4 T cells during C.neo infection. 
Mice were infected and a subset was depleted of TNFα as described above. 
Intracellular flow cytometry performed on enzymatically-digested lung at 14 dpi. 
T cells were sequentially gated on live cells/CD45+/CD3+/CD8-/CD4+, and then 
for expression of IFNγ (A), IL-17 (B), IL-13 (C) and TNFα (D). Statistical analysis 
was performed using student’s t-test. * p < 0.05; ***p < 0.001. 
 
Figure 3-4 Afferent phase TNFα results in long lasting Th2 
phenotype in the lungs.   
Magnetically sorted CD4+ cells isolated from 
mouse lung at 7, 14, and 28 dpi. CT values are 
presented as a heatmap of gene expression in 
TNFα-depleted infected mice relative to control-




magnetically separated from infected mouse lung and performed qPCR for iNOS 
and Arginase. The ratio of iNOS:Arginase mRNA expression was highly skewed 
towards iNOS production in control mice, but in TNFα-depleted mice, it was 
significantly skewed towards Arginase expression (Figure 3-5C). This motivated 
temporal analysis of the transcriptional profile of crucial DC1/DC2 genes 
expressed by the pulmonary CD11c cells. Results show that DCs from TNFα-
depleted mice suppressed mRNA for DC1-associated cytokines, chemokines, and 
receptors compared to those in control mice throughout the studied time points 
(Figure 3-6). Analysis of DC1/2 marker expression on gated DC populations 
from TNFα-depleted mice revealed significantly lower surface expression of 
MHCII and costimulatory molecule CD86 and significantly higher surface 
expression of DC2 polarization markers CD206 and Mac2 compared to those in 
control mice at 7 dpi (Figure 3-7). This suppression of MHCII and CD86 and 
elevation of CD206 and Mac2 surface expression remained consistent through all 
studied time-points (data not shown). Thus, DCs were able to sustain their 
polarization throughout infection and, importantly, DCs from TNFα-depleted 
mice maintained suppressed DC1 and enhanced DC2 profiles well after TNFα 
levels recovered. 
TNFα and IFNγ train DCs to maintain DC1 programming and suppress DC2 gene 
activation 
This sustained downregulation of DC1 genes after transient TNFα depletion, 
even when TNFα levels have recovered, suggested that during the initial week of 
infection, TNFα was required to stabilize a DC1 transcriptional profile. We 
addressed this hypothesis using an in vitro model in which bone-marrow derived  
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Figure 3-5 TNF α  results in variable 
mononuclear phagocyte accumulation, but 
strong classical activation phenotype 
throughout infection. 
Leukocytes from enzymatically-
digested lungs were cytospun onto 
charged microscope slides, fixed 
and stained with a diff-quick kit, 
and then cell populations were 
enumerated by light microscopy. 
Monocyte frequencies (A) and total 
numbers (B) were calculated. 
CD11c+ cells were isolated from 
lung leukocyte preparations by 
magnetic bead separation, and the 
ratio of iNOS to Arginase mRNA 
expression was calculated (C). N = 
4-7 from two separate, matched 
experiments. 
Statistical significance was 
determined by unpaired two-way 
ANOVA with multiple 
comparisons test or Student’s t-test 
where appropriate. * p < 0.05; ** p < 




Figure 3-6  Depletion of TNFα disrupts long-term stable DC1 phenotype. 
Magnetically sorted CD11c+ cells isolated from mouse lung at 7, 14, and 28 dpi. 
CT values are presented as a heatmap of gene expression in TNFα-depleted 
infected mice relative to control-treated infected mice. N = 4-7 from two separate, 
matched experiments. CT values are presented as a heatmap of gene expression 
in TNFα-depleted infected mice relative to control-treated infected mice. N = 4-7 
from two separate, matched experiments.  
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Figure 3-7 TNFα  is required for increased surface expression of MHCII and costimulatory molecules 
and suppression of DC2 marker surface expression. 
Extracellular flow cytometry performed on enzymatically-digested lung at 7 dpi. 
DCs were gated on CD45+/CD19-/CD3-/Ly6G-/CD11b+/CD11c+. DCs were 
then assessed for surface expression of MHCII (A), CD86 (B), CD206 (C), and 
Mac2/Gal3 (D). Representative histogram overlays are presented with bar 
graphs representing average percent positive. N = 8 from two separate, matched 
experiments. Statistical analysis was performed using student’s t-test. ** p < 0.01; 
***p < 0.001. 
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DC (BMDC) obtained from uninfected CBA/J mice were sequentially stimulated 
with DC1 (IFNγ) or DC2 (IL-4) polarizing cytokines in the presence or absence of 
TNFα. Specifically, BMDC were stimulated with IFNγ for 24 hours in the 
presence or absence of TNFα (training period), washed, and cultured with IL-4 
for 24 hours (challenge period), and DC1 and DC2 marker gene expression was 
assessed by qRT-PCR and flow cytometry (for schematic, see Figure 6-1). All data 
was compared to media only-treated BMDCs, and each experiment included 
TNFα only-treated controls, which did not differ significantly from media-only 
treatment (data not shown). First, we assessed the expression of DC1 activation 
hallmark iNOS and DC2 activation hallmark Fizz1 by mRNA expression. Cells 
treated and challenged with IFNγ (γ-γ) alone had high expression of iNOS and 
low expression of Fizz1, consistent with DC1 activation (Figure 3-8A and B, black 
bars). Cells treated with IFNγ alone and challenged with IL-4 (γ-4) had low 
expression of iNOS and high expression of Fizz1, consistent with DC2 activation 
(Figure 3-8A and B, clear bars). However, cells trained with IFNγ and TNFα 
together had sustained high expression of iNOS and low expression of Fizz1 
regardless of whether they were challenged with IFNγ or IL-4 (γα-γ and γα-4, 
respectively) (Figure 3-8A and B, dark and light grey bars, respectively). This 
decrease in DC1 polarization plasticity due to TNFα exposure during the 
training period will henceforth be referred to as TNFα training, similar to the 
innate immune training previously described (218, 219). 
We next tested whether TNFα could train a DC2 phenotype brought about by IL-
4 treatment or if the reduction in plasticity was unique to DC1/IFNγ-polarized 
cells. DCs were treated with IL-4 in the presence or absence of TNFα for 24  
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hours, washed, and challenged with IL-4 or IFNγ for 24 hours. DCs remained 
plastic to their environment regardless of whether TNFα was present (Figure 
3-8C and D), showing that TNFα training was specific to DC1/IFNγ 
polarization. 
In order to characterize the extent of TNFα training in DCs, we performed a 
screen for DC1 genes that encompassed many classical and alternative activation 
functional marker genes (Table 3-1). We observed a similar pattern of DC1 gene 
upregulation and DC2 gene downregulation in TNFα trained DCs in many 
classes of DC polarization and maturation genes, including antigen presentation 
and costimulatory molecules (MHCII, CD80, CD86), cytokines (IL-5, IL-12b, IL-
13), and phagocyte/antigen processing genes (iNOS, Fizz1, Mac2). Interestingly, 
not all genes associated with DC1 polarization responded to TNFα training– 
specifically, the DC1 genes CD40 and IFNγ– whereas the DC2 gene Arginase 
was also resistant to TNFα-mediated training.  
We next verified the TNFα training of MHCII and CD206 at the protein level 
using flow cytometry. γ-4 DCs had low MHCII surface expression, by both 
percent positive staining and mean fluorescence intensity, while γ-γ, γα-γ, and 
γα-4 DCs had both a higher percent positive cells and greater mean fluorescence 
intensity staining (Figure 3-9B). Conversely, γ-4 DCs had high CD206 surface 
expression and high mean fluorescence intensity, while γ-γ, γα-γ, and γα-4 DCs 
had low expression (Figure 3-9D). This TNFα training of MHCII and CD206 in 
vitro correlated to the sustained increase of MHCII and decrease of CD206 
surface expression from gated DCs in vivo. CFSE proliferation assays confirmed 
that all treatment groups underwent similar, limited proliferation during the  
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 Figure 3-8 DC1 and DC2 marker genes exhibit plasticity in vitro, which can be 
reduced by the addition of TNFα . 
Bone marrow-derived DCs from CBA/J mice were matured in GM-CSF over 7 
days. Cells were plated and exposed to IFNγ in the presence or absence of TNFα 
for 24 hours (training phase). Cells were then washed and treated with IL-4 
(challenge phase), or with IFNγ as a control. All qRT-PCR data is presented as 
relative to media-only-treated cells. (A and B) DC1 BMDCs polarized by IFNγ in 
the presence or absence of TNFα during the training phase were challenged with 
IL-4 to determine plasticity of DC1 and DC2 marker gene expression. iNOS (A) 
and Fizz1 (B) expression was assessed at the mRNA level by RT-qPCR. (C and D) 
DC2 BMDCs polarized by IL-4 in the presence or absence of TNFα during the 
training phase were challenged with IFNγ to determine whether training is 
specific for DC1 or also applicable to DC2. iNOS (G) and Fizz1 (H) levels were 
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analyzed by RT-qPCR. Statistical analysis was performed using 1-way ANOVA.* 
p < 0.05; ** p < 0.01; ***p < 0.001. 
 
 
Figure 3-9 TNFα-mediated training observed at the mRNA level can also be seen in surface expression 
of DC1 and DC2 markers at the protein level. 
 (A and B) DC1 BMDCs polarized by IFNγ in the presence or absence of TNFα 
during the training phase were challenged with IL-4 to determine plasticity of 
DC1 and DC2 marker gene expression. MHCII (A) and CD206 (B) expression was 
assessed at the mRNA level by RT-qPCR. 
(C and D)  DC1 BMDCs polarized by IFNγ in the presence or absence of TNFα 
during the training phase were challenged with IL-4 to verify plasticity of surface 
marker expression at the protein level. MHCII (C) and CD206 (D) expression was 
assessed on the cell surface by flow cytometry. Representative histogram 
overlays are presented with bar graphs representing average percent positive.  
Statistical analysis was performed using 1-way ANOVA.* p < 0.05; ** p < 0.01; 




Table 3-1 Genes screened for TNFα-mediated training 
Tables of genes organized according to class of gene: DC1, DC2, maturation, or 
epigenetic modification enzymes. Patterns denoted are as follows:  
None: no significant differences between treatments. 
Up in DC1: γ-γ, γα-γ, γα-4 cells all have increased expression 
Up in DC2: γ-4 cells have increased expression 
Up with IL-4 challenge: up in γ-4 or γα-4 treatment, these genes appear to be not 
TNFα-trainable 
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Up in non-trained DC: γ-γ and γ-4 have increased expression 
Up in non-trained DC1: γ-γ alone has increased expression. 
Unclear: significant differences exist between some treatments, but the 
relationship between stimulus and gene regulation is unclear (and is not any 
other specified pattern). 
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training and challenge phases (Figure 3-10), which reinforces the idea that these 
changes are not being skewed by differential proliferation between treatment 
groups. 
Finally, we tested whether secreted cytokines, in addition to intracellular and 
surface markers, responded to TNFα-mediated training. IL-12b was induced in 
γ-γ and γα-trained cells, but not in γ-4 DC2s (Figure 3-11A), whereas IL-13 was 
induced only in γ-4 cells and not in γ-γ or γα-trained DC1s (Figure 3-11B). Thus, 
TNFα was able to train DC1s to maintain high expression of DC1 functional 
surface proteins, cytokines, and polarization markers and low expression of DC2 
functional surface proteins, cytokines, and polarization markers, even when DCs 
were challenged with pro-DC2 cytokines. 
TNFα is required for induction of DC1 programming in the presence of cryptococcal 
antigen 
Cryptococcal antigens are known modulators of DC activation (148, 149, 151, 
157). Therefore, we next determined whether the addition of heat-killed C.neo 
(HKC) to the DC cultures during the training period would alter DC1 and DC2 
marker expression. Surprisingly, γ-γ DCs were unable to upregulate IL-12b in 
the presence of HKC and exhibited IL-12b transcript levels similar to γ-4 DC2s; 
in contrast, γα-γ and γα-4 TNFα-trained DC1s upregulated DC1 cytokine 
expressions (Figure 3-11C), suggesting they were able to overcome the 
immunomodulatory effects of the HKC. We observed a similar pattern with 
iNOS expression upon exposure to HKC where γ-γ DCs were unable to 
upregulate iNOS transcript (data not shown). Both γ-γ and γ-4 DCs increased  
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Figure 3-10 BMDCs receiving different training and challenge phase stimulations do not exhibit 
differences in proliferation. 
BMDCs were loaded with CFSE to track proliferation in order to ensure that 
differences in mRNA expression analyzed in BMDC experiments based on  
 Figure 3-8 could not be attributed to differences in proliferation between the 
treatment groups. There was a slight but significant difference in proliferation 
between γ-γ cells and γα-4 treated cells that had moderate CFSE dilution 
(approx. 4 divisions), but no other significant differences in proliferation. 





expression of IL-13 mRNA when stimulated with HKC, but TNFα training 
prevented DC IL-13 upregulation (Figure 3-11D). To validate this in vivo, we 
analyzed serum from infected mice and found that infected control mice had 
consistently elevated IL-12p70 and low IL-13 levels consistent with DC1/Th1 
skewing, while serum from the TNFα-depleted infected mice had suppressed IL-
12p70 and elevated IL-13 levels (Figure 3-11E and F) throughout infection, 
consistent with DC2/Th2 systemic polarization. Thus, not only were TNFα-
trained DCs resistant to changes in polarization mediated by cryptococcal 
antigen, TNFα was uniquely necessary to overcome cryptococcal antigen-
mediated suppression of DC1 activation. 
Adoptive transfer of TNFα-trained DC1s rescues Th1 polarization in CD4 T cells from 
TNFα-depleted mice 
We next tested whether TNFα -trained DCs were sufficient to skew Th 
polarization in TNFα-depleted, C.neo-infected mice. As detailed in Figure 3-12A, 
we infected and TNFα-depleted CBA/J mice on day 0. At 1 dpi and 8 dpi, mice 
received i.v. transfer of 1 million TNFα-trained DC1s (γα) or untrained DC1s   
(γ only), and mice were sacrificed at 14 dpi to assess the polarization of CD4 T 
cells. The CD4 T cells of TNFα-depleted mice that received γα DCs had a 
significant increase in frequency of cells staining positively for IFNγ, as well as 
increased intensity of IFNγ staining (Figure 3-12B and C). Untrained DC1s were 




Figure 3-11 TNFα-mediated training applies to secreted cytokines in the presence of antigen in vitro and 
in vivo. 
(A-D) BMDCs treated as in  
 Figure 3-8 but including heat-killed C.neo (HKC) during the training phase were 
assessed for IL-12b (A, B) and IL-13 (C, D) cytokine production by RT-qPCR to 
determine TNFα training of DC1 and DC2 cytokines and the effect of HKC on 
this training. Note the modulation of untrained, IFNγ-treated DCs (first column, 
C and D) by HKC preventing DC1 gene induction and inducing DC2 gene 
expression. (E and F) Serum levels of IL-12p70 (E) and IL-13 (F) from infected 
mice at 0, 7, 14, and 28 dpi were assessed by cytometric bead array. A, C: N = 18 
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from six separate, matched experiments; B, D: N = 9 from three separate, 
matched experiments; E, F: N = 4-12 from three separate, matched experiments. 
Statistical significance was determined by unpaired two-way ANOVA with 
multiple comparisons test. * p < 0.05; ** p < 0.01; ***p < 0.001, or otherwise 
indicated. 
 
Figure 3-12 Transfer of TNFα-trained DCs rescues Th1 polarization in TNFα-depleted, C.neo-infected 
mice.   
BMDCs were generated as in Figure 3-7, TNFα –trained or treated with IFNγ 
alone, and 1 million cells were transferred into infected, TNFα-depleted mice 
according to the schematic in (A). A greater frequency of CD4 T cells harvested at 
14 dpi from mice receiving TNFα-trained DCs made IFNγ than from mice that 
received untrained DC1 (B). CD4 T cells from mice receiving TNFα-trained DCs 
also had a higher intensity of staining than CD4 T cells from mice that received 
untrained DC1 (C). N = 5. Statistical significance was determined using student’s 




TNFR1 and TNFR2 contribute non-redundantly to TNFα-mediated training in DCs 
Lastly, we wanted to determine which receptor for TNFα was responsible for 
the observed TNFα-mediated training, TNFR1 or TNFR2. Blocking antibodies 
for TNFR1, TNFR2, or TNFR1 and 2 together were added to wells of the BMDC 
cytokine cycling experiments during the training phase, and RNA was harvested 
to assess loss of training. We found that iNOS training (upregulation) was 
partially blocked when TNFR1 was inhibited (Figure 3-13B), partially blocked 
when TNFR2 was inhibited (Figure 3-13C), but completely blocked upon dual 
receptor blockade (Figure 3-13D). Similarly, Fizz1 training (downregulation) was 
partially blocked when TNFR1 was inhibited (Figure 3-14B), partially blocked 
when TNFR2 was inhibited (Figure 3-14C), but completely blocked upon dual 
receptor blockade (Figure 3-14D). Thus, complete TNFα  training requires 
signaling from both TNFR 1 and TNFR2. 
Discussion 
The present study examines the requirement for TNFα during the early stages 
of C.neo infection. We fully immunophenotyped pulmonary CD4 T cells (Figure 
3-2, Figure 3-3, Figure 3-4), through 28 dpi, and show that TNFα mediates 
lasting protective immune responses. We determined that DCs activated in the 
presence of TNFα adopted a lasting DC1 phenotype and primed protective 
Th1/Th17 immune responses (Figure 3-5, Figure 3-6, Figure 3-7) sufficient to 
change the polarization of T cells from C.neo-infected, TNFα-depleted mice from  
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Figure 3-13 TNFα-mediated DC1 gene training is reliant on both TNFR1 and TNFR2 signaling.   
BMDCs were treated with IFNγ and/or TNFαduring the training phase and IL-4 
or IFNγ during the challenge phase as in  
 Figure 3-8. During the training phase, cells received either: no blocking 
antibodies (A), TNFR1 blocking antibodies (B), TNFR2 blocking antibodies (C), 
or TNFR1 and TNFR2 blocking antibodies (D). mRNA expression of iNOS was 
assessed for each group. Note the partial loss of training with each individual 
TNFR inhibitor, and the complete loss of training with blockade of both TNFR. 
Statistical significance was determined by unpaired two-way ANOVA with 




Figure 3-14 TNFα-mediated DC2 gene training is mediated by both TNFR1 and TNFR2 signaling. 
BMDCs were treated with IFNγ and/or TNFαduring the training phase and IL-4 
or IFNγ during the challenge phase as in  
 Figure 3-8. During the training phase, cells received either: no blocking 
antibodies (A), TNFR1 blocking antibodies (B), TNFR2 blocking antibodies (C), 
or TNFR1 and TNFR2 blocking antibodies (D). mRNA expression of Fizz1 was 
assessed for each group. Note the partial loss of training with each inhibitor 
individually, and complete loss of training with both TNFR blocking antibodies. 
Statistical significance was determined by unpaired two-way ANOVA with 
multiple comparisons test. * p < 0.05; ***p < 0.001. 
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Th2 to Th1 (Figure 3-12). Finally, we linked TNFα-mediated DC training to the 
nonredundant signaling of both TNFR1 and TNFR2 (Figure 3-13, Figure 3-14). 
The data presented in this manuscript represents a significant advance in our 
understanding of the necessity for TNFα during fungal infection.  
We find here that early TNFα signaling is responsible for the generation of a 
stable DC1 population that sustains its robust DC1 phenotype throughout 
several weeks of infection, which is the time required for efficient clearance of 
C.neo. The sustained DC1 presence leads to generation of lasting protective Th1 
anticryptococcal immunity. Consistently robust Th1/Th17 immune responses are 
necessary for control and clearance of C.neo from the lungs (3, 64, 69, 72, 169). 
Previous work using this model of transient TNFα depletion has shown that 
TNFα is critical for early induction of pro-Th1 cytokines at the global lung level 
(85). Those studies also suggested that immature DCs migration to the draining 
lymph nodes may account for the subsequent development of defective, non-
protective immune responses (84). However, as we show here, the DCs in the 
C.neo-infected lung in the absence of TNFα display many characteristics of 
mature DCs, with robust co-expression of markers of DC2 activation (of which, 
some are shared with markers of immaturity, such as CD206) (Figure 3-5C, 
Figure 3-6, Figure 3-7). Our adoptive transfer studies showed conclusively that 
DCs activated with TNFα and IFNγ combined (trained DCs) are uniquely able to 
enhance Th1 polarization in C.neo-infected TNFα-depleted mice, in contrast with 
unstable DC1s (activated with IFNγ alone), which were unable to improve the 
Th1 response (Figure 3-12). Thus, we conclude that TNFα signaling is a necessary 
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component for the robust and stable DC1 phenotype, and perpetuates the robust 
and stable Th1 response necessary for clearance. 
Our in vitro modeling clearly shows fundamental differences in how DCs 
respond to changing environments (i.e. pro-DC1 to pro-DC2), depending on how 
they were initially activated. While γ-only-activated DCs (γ- γ) had an obvious 
DC1 phenotype, this phenotype switched to DC2 upon changing the cytokine 
environment to pro-DC2 (γ-4). However, DCs activated with IFNγ and TNFα 
(γα-γ or γα -4) had the same obvious DC1 phenotype as γ-only DCs, but they 
maintained their DC1 phenotype upon changing the cytokine environment to 
pro-DC2. γα DCs reacted differently than γ-only DCs to the same secondary 
stimulus.  
Our in vitro experiments show that TNFα-mediated training of DCs is not a 
phenomenon restricted to C.neo infection; indeed, initial testing of the model 
took place in the absence of an antigen (Figure 3-8, Figure 3-9). This is unique in 
the field of innate immune training, where reports of training in monocytes occur 
in response to sepsis and serum LPS (188, 192, 220, 221), and in response to 
fungal β-glucans and the BCG vaccine (218, 219, 222, 223). For our model, in the 
absence of C.neo antigen, DC1 polarization can be induced by treatment with 
IFNγ alone, but this is not a long-lasting DC1 polarization, and can quickly 
change to DC2 in response to changing cytokine environment (Figure 3-8, Figure 
3-9). However, in the presence of C.neo antigen– known to be a suppressor of DC 
classical activation (148, 149, 151, 157)– our experiments show that IFNγ alone 
cannot induce DC1 polarization (Figure 3-11), and in the presence of C.neo 
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antigen, TNFα is absolutely necessary to both induce DC1 and suppress DC2 
cytokine expression. 
Interestingly, our data reveals that not all DC1 genes are subject to TNFα-
mediated training, nor are all DC2 genes stably downregulated by TNFα training 
when followed by IL-4 challenge in vitro (Table 3-1). This division of genes into 
“TNFα-trainable” and “TNFα non-trainable” expands on work done by Foster et 
al. in 2007 (190) in a model of endotoxin tolerance, wherein specific genes (i.e. 
RANTES) could always be expressed regardless of whether the macrophage was 
endotoxin-tolerant, while other genes (i.e. IL-6) were consistently suppressed in 
endotoxin-tolerant macrophages but not in non-endotoxin-tolerant macrophages. 
A similar phenomenon may be occurring in TNFα-trainable genes versus non-
TNFα-trainable genes. 
The TNFα  receptors necessary for signaling during cryptococcal infection, 
particularly in DCs, have not been elucidated yet. We found that blocking each 
TNFα  receptor individually decreased the magnitude of TNFα -mediated 
training, but did not completely ablate training, while blockade of both receptors 
did ablate training (Figure 3-13, Figure 3-14). Work by Dong et al. implicated 
TNFR p75-80 (TNFR2) on the neutrophil cell surface as a target of immune 
modulation by cryptococcal polysaccharide capsule (224). Further, soluble 
TNFR2 in the cerebral spinal fluid of cryptococcal meningitis patients was 
correlated with survival (225). However, neither of these studies 1) investigates 
the role of TNFα signaling through the receptors, instead using them as markers; 
2) directly reference DCs; and 3) specifically address and/or exclude the 
contributions of TNFR1 (due in part to complications with antibodies against 
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TNFR1 at the time of these studies). Thus, our findings that each receptor 
contributes non-redundantly to DC training in vitro represent a significant step 
forward. 
Based on our findings from this paper and other recent work from our 
laboratory, we have assembled a model mechanism for the requirement of TNFα 
early during C.neo infection. Early signaling through TNFα receptors in DCs is 
necessary to classically activate DCs upon initial exposure to C.neo, and to 
maintain that polarization throughout many weeks of infection (Figure 3-5, 
Figure 3-6, Figure 3-7A, B). These DC1 cells matured in the presence of TNFα are 
resistant to changing their polarization caused by changes in cytokine 
environment (Figure 3-8, Figure 3-9) and/or by immune modulation by C.neo 
antigen (Figure 3-11). For human patients receiving TNFα monoclonal antibody 
therapy, this defect in DC1 activation may be responsible for their heightened 
susceptibility to C.neo and other infections, such as Histoplasma capsulatum or 
Mycobacterium tuberculosis. Based on our adoptive transfer studies (Figure 3-12), a 
potential therapy whereby DCs from the same patient are harvested and re-
polarized may prove successful in controlling and eventually clearing infection. 
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Chapter 4 Epigenetic modification of DCs and DC 




TNFα is required for protective Th1 immunity to Cryptococcus neoformans (C.neo) 
and these effects are linked to the stable, early classical activation of dendritic 
cells (DC1), preventing alternative (DC2) activation. We hypothesized that TNFα 
trains DC1s by inducing activating epigenetic modifications of key DC1 genes. 
We first assessed levels of the activating histone modification histone 3 lysine 4 
trimethylation (H3K4me3) signature in DCs in vitro and in vivo. TNFα-trained 
BMDCs had a high H3K4me3 signature; DC1 DCs from 7 dpi C.neo-infected 
mouse lung also had high H3K4me3, while DC2 DCs from 7 dpi TNFα-depleted 
C.neo-infected mouse lungs did not. We performed chromatin 
immunoprecipitation from CD11c+ lung cells and found that DC1 genes iNOS 
                                                
4 Excerpts of this chapter taken from: 
Eastman, A.J., J. Xu, N. Potchen, A. denDekker, L. M. Neal, G. Zhou, A. 
Malachowski, S. Kunkel, J. J. Osterholzer, and M. A. Olszewski. TNFα is 
necessary for long lasting protective immunity to fungal infection through 
epigenetic stabilization of classically activated dendritic cells and bone marrow 
dendritic cell precursors. In submission at Science Immunology. 
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and IL-12b were associated with the H3K4me3 modification in DC1s from C.neo-
infected mice at a greater rate than from TNFα-depleted C.neo-infected mice. 
The H3K4me3 signature appears to be dependent on the H3K4 methyltransferase 
MLL1 in TNFα -trained DCs, as opposed to being mediated by H3K4 
demethylase KDM5d in DC2 cells. Because the DC1 polarization was so long 
lasting in vivo, we assessed myeloid precursor cells and pre-DCs within the bone 
marrow compartment for evidence that they were being recruited already 
predisposed to DC1 or DC2 activation. Pre-DCs from C.neo-infected mice sorted 
by flow cytometry had increased H3K4me3 signature consistent with those of 
pulmonary DC1s, while pre-DCs from TNFα-depleted C.neo-infected mice did 
not. Finally, BMDCs matured ex vivo from infected mouse bone marrow were 
assessed for TNFα-mediated training and plasticity; BMDCs from C.neo-infected 
mice already exhibited TNFα-mediated training, while BMDCs from TNFα-
depleted C.neo-infected mice were unable to responds to TNFα. We conclude 
that histone modifications in DC are significantly altered by TNFα, and that this 
correlates with increased DC1 stability during protective responses to C.neo 
infection, and further extends to pre-polarization of DC precursors in the 
infected mouse bone marrow compartment. 
Introduction 
In the previous chapter, we showed that afferent-phase TNFα was necessary for 
long-lasting efferent Th1/Th17 immune responses. DCs, responsible for priming 
and restimulating T cells during C.neo infection, had stable and robust DC1 
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programming during both the efferent and afferent phases of the immune 
response to C.neo infection in the presence of TNFα, and thus primed and 
perpetuated protective Th1 T cell-mediated immunity throughout the infection. 
We modeled this in vitro, and show a unique phenotype of DC reliant on the 
combined signaling of TNFα  and IFNγ ; these DCs maintained DC1 
polarization even upon challenge with pro-DC2 environments. We determined in 
vitro that the TNFα-mediated training was due to both TNFR1 and TNFR2. This 
addressed the cellular mechanism behind the necessity for TNFα during C.neo 
infection, but did not yet address the molecular mechanism. The following 
experiments in Chapter 4 determine the mechanism behind TNFα-mediated 
training of DCs.  
It is largely unknown how innate immune cells remember to respond to 
particular pathogens throughout infection– particularly chronic infections– 
although epigenetic modifications are increasingly appreciated as a potential 
mechanism. TNFα signaling itself has been shown to stimulate chromatin 
modification in endothelial cells (186), but its effects on immune cell chromatin 
remodeling during infection remain unstudied. Trained immunity has been 
elegantly characterized in effector macrophages in a model of restimulation 
following acute fungal infection (218, 219, 222), as a lasting consequence of sepsis 
in circulating monocytes (188, 192, 220, 226), and proposed as the mechanism 
behind broad antimicrobial effects of infant BCG vaccination (223, 227, 228). 
However, much of these studies focus on the effector function of myeloid cells, 
and not on priming of adaptive immune responses. 
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In this chapter, we determined the molecular mechanism behind TNFα -
mediated training of DCs, and propose a mechanism for perpetuating the stable 
DC1 population in vivo. Because the TNFα depletion only lasts 7-14 days, and 
TNFα levels recover in C.neo-infected mice, but the non-protective immune 
response to C.neo persists many weeks after TNFα recovery, we hypothesize 
that TNFα is responsible for epigenetic modifications that promote and/or 
reinforce DC1 programming. Thus, these TNFα-trained DC1s are able to prime 
Th1 responses in TNFα-depleted C.neo-infected mice. To address this, we first 
assessed differences in selected epigenetic modifications at the global level in 
TNFα-trained DCs, untrained DC1s, and DC2s in vitro and in vivo. We then used 
chromatin immunoprecipitation to determine whether DC1 or DC2 genes are 
associated with activating epigenetic modifications. We tested which epigenetic 
modification enzyme(s) are responsible for our TNFα-trained DC phenotype. 
Finally, we performed ex vivo experiments on the bone marrow from C.neo-
infected mice to probe whether recruited monocyte-derived DCs differ in the 
presence or absence of TNFα.  
Results 
TNFα and IFNγ signaling results in epigenetic activation of DC1 genes in an MLL1-
dependent manner 
The sustained changes to DC polarization and plasticity observed in vivo and in 
vitro from Chapter 3 suggested to us an epigenetic mechanism. We first broadly 
characterized the H3K4me3 profile of DC1, DC2, and TNFα-trained DCs in vitro 
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by intranuclear flow cytometry. Non-TNFα-trained DC1 and DC2 cells had a 
similar, low H3K4me3 signature and a lower frequency of cells staining intensely 
for H3K4me3 (Figure 4-1A, black and white bars). Both γα-γ and γα-4 TNFα-
trained DCs had an increase in both the frequency and intensity of staining for 
H3K4me3, further suggesting that TNFα-trained DCs are distinct from both DC2 
and untrained DC1 cells (Figure 4-1A, grey bars). We confirmed these findings in 
vivo from DCs isolated from the lungs of infected mice at 7 dpi. Sorted DCs from 
infected control mice, which we have shown to be DC1, had higher levels of 
H3K4me3 compared to DCs from infected TNFα-depleted mice (DC2-skewed) or 
uninfected mice (Figure 4-1B). These data supported our hypothesis that 
epigenetic mechanisms, specifically changes in the activating histone 
modification H3K4me3, are involved in TNFα-mediated stabilization of DCs. 
We next performed chromatin immunoprecipitation on CD11c+ cells 
magnetically separated from the lungs of mice at day 14 post-infection to 
determine whether changes in the global H3K4me3 signature of the DCs 
corresponded to the activation or repression of relevant DC1 or DC2 genes in 
vivo. This is a time point where there is a small but significant difference in 
antigen levels between the two treatment groups, but where TNFα levels have 
recovered in TNFα-depleted mice. Using antibodies specific for H3K4me3, we 
pulled down antibody-histone-DNA complexes, purified the DNA, and 
performed qPCR with primers specific for the promoter regions of key DC1 
genes. We observed that infection with C.neo resulted in strong enrichment of 
H3K4me3 at the iNOS and IL-12b promoter regions of control mice (Figure 4-2 A 
and B), indicating epigenetic activation of these genes, which is consistent with  
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Figure 4-1 High H3K4me3 signature associated with TNFα-trained DC1s in vitro and in vivo. 
BMDCs were treated as in  
 Figure 3-8 and subjected to flow cytometric analysis (A) or cell populations were 
flow cytometry-gated DCs from 7 dpi enzymatically digested mouse lungs (B). 
Cells were stained for intranuclear expression of H3K4me3 and analyzed by flow 
cytometry. Data is presented as representative histogram, percent positive/high, 




their increased mRNA expression. In contrast, CD11c+ cells from TNFα-depleted 
mice showed significant suppression of H3K4me3 signature at these promoter 
regions (Figure 4-2A and B) consistent with their decreased mRNA expression. 
There were no differences in enrichment of H3K4me3 for the β-actin promoter, 
our positive control (Figure 4-2C). Interestingly, in the infected, TNFα-depleted 
mice, we observed a trend towards enrichment of H3K4me3 at the promoter 
region of Fizz1 (Figure 4-2D), which was not seen in the infected control mice.  
To mechanistically link the effects of TNFα signaling with an increased 
H3K4me3 signature, we next assessed the induction of H3K4 histone 
demethylase KDM5d and H3K4 histone methyltransferse MLL1, as these two 
kinases are largely responsible for proximal gene repression/de-repression at 
H3K4 (229, 230). KDM5d mRNA expression was not induced by TNFα or 
uniquely induced in DC1 or DC2 cells (Figure 4-3A). However, MLL1 mRNA 
expression was highly induced in TNFα-trained DC1s, both in the presence and 
absence of cryptococcal antigen (Figure 4-3B). Interestingly, the addition of TNFα 
alone to BMDCs was insufficient to increase MLL1 mRNA levels (Figure 4-3C). 
Furthermore, TNFα-depletion resulted in significant suppression of MLL1 
mRNA levels in CD11c+ cells isolated from the lungs of infected mice at both 
early (7 dpi) and late (28 dpi) timepoints (Figure 4-3D).  
MLL1 is essential for adding the mono- and di-methylation onto H3K4me3, 
while MLLs 3 and 4 add the final trimethylation (179). Using the MLL1 inhibitor 
MM102 (231) during the initial 24-hour training phase, followed by the 24-hour 
challenge phase without the inhibitor, we found that inhibition of MLL1 did not 
prevent induction of DC1 genes iNOS and IL-12b in γα-γ DCs (Figure 4-4A and  
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Figure 4-2 DC1 gene promoter regions of DCs matured in the presence of TNFα  and cryptococcal 
antigen in vivo are associated with H3K4me3. 
 
Mice were infected and/or TNFα-depleted as in Figure 3-1. CD11c+ cells were 
magnetically sorted from enzymatically digested mouse lung at 14 dpi, then 
fixed and frozen at -80 (data is pooled from 12 samples each treatment from three 
separate, matched experiments). Chromatin immunoprecipitation was 
performed using anti-H3K4me3 or control antibodies. RT-qPCR was performed 
on purified immunoprecipitated DNA using primers specific for iNOS (A), IL-
12b (B), β-actin (C) and Fizz1 (D) promoter regions.  






Figure 4-3 MLL1 mRNA expression is induced by TNFα  and IFNγ  combined, but not separately in 
vitro and is induced only in DC1s from infected control animals in vivo. 
 (A and B) BMDCs were treated as in  
 Figure 3-8. mRNA levels of KDM5d (A) and MLL1 (B) were assessed for 
induction in TNFα-trained DCs by qRT-PCR. N = 18 from six separate, matched 
experiments. 
(C) MLL1 induction was subsequently tested in the indicated conditions with 
and without HKC to determine specificity of induction. †  represents statistically 
significant difference between γα and γ alone, while ‡  represents statistically 
significant difference between γαHKC and γHKC alone. N = 9-18 from separate, 
matched experiments. 
D) Mice were infected and a subset was TNFα depleted as in Fig. 1. Magnetically 
separated CD11c + cells from enzymatically digested mouse lung at 7 dpi (early) 
and 28 dpi (late) were assessed for MLL1 expression by RT-qPCR. N = 6-8 from 
two separate, matched experiments. 
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B). However, when TNFα-trained DCs were challenged with IL-4 after MLL1 
inhibition during the training phase, the training was ablated and γα-4 DCs were 
plastic to their cytokine environment similar to untrained DCs (Figure 4-4A and 
B). This finding shows that inhibition of MLL1 prevents the TNFα-mediated 
training of DC1 genes.  
TNFα is required for DC1 pre-programming in the bone marrow of C.neoformans-
infected mice 
Because the duration of the TNFα-trained pulmonary DC phenotype in vivo 
during C.neo infection last far longer than the expected lifespan of inflammatory 
DCs in the lungs, we hypothesized that myeloid precursor populations in the 
bone marrow of C.neo-infected mice may require TNFα to pre-program DC-
precursors into DC1s. Initial characterization of the bone marrow compartment 
revealed no significant differences in overall cell numbers until 28 dpi, when the 
TNFα-depleted mice had a reduced total bone marrow population relative to 
isotype-treated mice (Figure 4-5A). Furthermore, general myeloid precursor cells 
(MPCs: lin- /SCA1-/Flt3+/CD115+) and specific pre-DCs (pre-DCs: lin-/SCA1-
/Flt3+/CD115+/c-kit-) showed no effect of TNFα depletion on frequencies of DC 
precursors relative to total bone marrow cells (Figure 4-5B, C; see Figure 6-4 for 
gating). Subsequent assessment of global H3K4me3 signature within MPCs by 
intranuclear flow cytometry demonstrated that greater numbers of MPCs in 
isotype-treated infected mice displayed high H3K4me3 signature compared to 
MPCs in TNFα-depleted mice, at 14 dpi (Figure 4-5D). Furthermore, intranuclear 
flow cytometry revealed strongly increased mean fluorescence intensity of 
H3K4me3 in MCP cells from control mice compared to TNFα-depleted mice by  
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Figure 4-4 Training of DC1 genes by TNFα  and IFNγ  is abrogated by inhibition of histone 
methytransferase MLL1 during the training phase. 
MLL1 inhibitor MM102 was added during the training phase of in vitro 
experiments as in  
 Figure 3-8. mRNA was isolated after the challenge phase and assessed for DC1 
markers iNOS (A) and IL-12b (B) by RT-qPCR. N = 6 from two separate, matched 
experiments. 
Statistical significance was determined by two-way ANOVA with multiple 






Figure 4-5 The bone marrow compartment, including MPCs and pre-DCs, is roughly similar between 
C.neo-infected mice, regardless of TNFα  depletion. 
(A) Mice were infected and/or TNFα depleted as in Figure 1. One femur from 
each mouse was dissected, the marrow flushed, and total cell numbers 
enumerated by light microscopy. 
(B and C) Counted marrow cells were stained for flow cytometric analysis. 
Myeloid precursor cells (MPCs) were gated as: live/lin-/SCA1-/Flt3+/CD115high 
(B). Dendritic cell precursors (pre-DCs) were gated as live/lin-/SCA1-
/Flt3+/CD115high/c-kitlow (C). 
Statistical significance was determined by two-way ANOVA with multiple 
comparisons test or student’s t-test where appropriate. * p < 0.05; ** p < 0.01. 
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at both 7 and 14 dpi (Figure 4-5D). To confirm and visualize these findings, we 
magnetically isolated CD11b+ bone marrow cells and used antibody staining and 
fluorescence microscopy to further demonstrate that pre-DCs from TNFα-
depleted mice displayed reduced H3K4 trimethylation staining compared to that 
of control mice (Figure 4-6). Taken together, these findings support the idea that 
TNFα signaling may pre-program bone marrow pre-DCs during infection. 
Finally, to determine whether these pre-DCs could be arriving to the lung 
predisposed to DC1 or DC2 polarization, we collected bone marrow from 4 
cohorts of mice: 1) uninfected isotype-treated mice; 2) uninfected anti-TNFα-
treated mice; 3) isotype-treated mice at 7 dpi; and 4) anti-TNFα-treated mice at 7 
dpi. Bone marrow obtained from each cohort of mice was cultured for 7 days in 
the presence of GM-CSF to generate BMDCs. Thereafter, these BMDC from 4 
groups were used in our TNFα-training and challenge experiments. BMDCs 
obtained from uninfected mice treated with either isotype-control or anti-TNFa 
antibody were receptive to TNFα-mediated training; γ-γ cells adopted a DC1 
polarization, γ-4 cells became DC2 polarized, and the TNFα-trained DCs resisted 
DC2 polarization by IL-4 challenge (Figure 4-7A). In contrast, the DCs from 
infected mice treated with either isotype-control or anti-TNFα antibody did not 
respond to TNFα training or to IFNγ or IL-4 challenges. Rather, BMDCs matured 
from infected, isotype-treated mice maintained high expression of DC1 marker 
iNOS regardless of treatment (Figure 4-7B, right half), indicating that DCs from 
the bone marrow of C.neo-infected mice with intact TNFα signaling were already 
programmed for DC1 polarization. In contrast, BMDCs matured from C.neo-
infected mice depleted of TNFα displayed uniform downregulation of iNOS  
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Figure 4-6 Myeloid precursor cells of the bone marrow in infected control mice bear high H3K4me3 
signature consistent with DC1 phenotype observed in lungs. 
 
 (A) Flow cytometric analysis of H3K4me3 signature in MPCs isolated from 14 
dpi bone marrow. Data is shown as representative histogram, percent 
H3K4me3high and mean fluorescence intensity staining. Dotted red bar indicates 
% high in uninfected mouse MPCs.  
(B) From 14 dpi mice, final stage pre-DCs (CD11b+) were sorted by magnetic 
bead separation. 1 x 105 cells were cytospun onto slides, fixed, and stained for 
H3K4me3 (red) and Fizz1 (green), followed by the appropriate fluorescently-
conjugated secondary antibodies, and DAPI (blue). Slides were imaged by 
confocal microscopy.   
Statistical significance was determined by two-way ANOVA with multiple 
comparisons test or student’s t-test where appropriate. * p < 0.05; ** p < 0.01. 
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Figure 4-7 Myeloid precursor cells in the bone marrow of infected mice are predisposed to DC1 
polarization in the presence of TNFα. 
Bone marrow was taken from mice at 7 dpi following infection and/or TNFα 
depletion. Four femurs from each condition were pooled. Bone marrow was then 
matured over 7 days in the presence of GM-CSF. The loosely adherent fraction 
was harvested and plated, and subjected to cytokine training and challenge 
phases as in Figure 2. mRNA was isolated and RT-qPCR performed for iNOS on 
the marrow matured from each condition. ex vivo BMDCs from uninfected mice 
responded to TNFα training regardless of TNFα depletion (A).  ex vivo BMDCs 
from infected control mice all had high DC1 gene induction regardless of further 
training or challenge (B, left half), while ex vivo BMDCs from infected TNFα 
depleted mice had no induction of DC1 genes regardless of further training or 
challenge (C, right half). Data is presented as normalized to each graph’s “control 
day 7 γ-γ” treatment. ‡ represents statistically significant differences between the 
indicated values in the TNFα depleted samples relative to “control day 7 γ-γ” 
values. Statistical significance was determined by two-way ANOVA with 




regardless of training or challenge (Figure 4-7B, left half), suggesting that the 
DCs from TNFα-depleted were not predisposed to a DC1 polarization, and 
remained unresponsive to a subsequent DC1 polarizing stimulation. 
Discussion 
In this chapter, we have determined that the cellular basis for long lasting 
protective immunity is tied to association of DC1 gene promoters with the 
activating histone modification H3K4me3 (Figure 4-1 and Figure 4-2,), which 
occurs in an MLL1-dependent manner (Figure 4-3 and Figure 4-4); and traced 
these modifications back to the myeloid progenitor cells in the bone marrow 
(Figure 4-5, Figure 4-6, and Figure 4-7). Further, we have found that TNFα-
mediated epigenetic training of DCs occurs both with and without antigen, 
which extends the application of TNFα-mediated innate immune training 
beyond anticryptococcal immune responses and into the realm of basic DC 
biology and function. Epigenetic modifications to innate immune cells and their 
precursors described herein serve as an attractive general mechanism behind the 
requirement for early TNFα in generation of protective immunity. In addition to 
increased risk of C.neo infection, similar mechanisms are likely contributors to 
increased susceptibility to Histoplasma capsulatum and Mycobacterium tuberculosis 
in patients on TNFα  monoclonal antibody therapy, which is broadly 
documented in the literature (30, 232, 233). To our knowledge, this is the first 
time that TNFα has been linked to epigenetic modification of DC1 immune genes 
during a primary immune response to a pathogen (C.neo). 
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We show here that the molecular basis for perpetuating this DC1 programming 
during TNFα-training is via epigenetic modifications to the H3K4 residue. The 
global H3K4me3 signature is elevated in IFNγ/TNFα-trained DCs, while this 
was absent from IFNγ-only-treated DCs (Figure 4-1), despite the fact that both 
types of DCs were phenotypically DC1. Furthermore, TNFα is necessary for 
DC1s to “remember” to maintain DC1 polarization despite subsequently 
changing environments, through the specific enrichment of activating histone 
modification H3K4me3 at DC1 gene promoter regions (iNOS, IL-12b; Figure 4-2). 
We also show that TNFα signaling leads to changes in H3K4me3 through the 
histone methyltransferase MLL1. MLL1 becomes uniquely upregulated in γα 
DCs (and not in γ-alone or α-alone DCs; Figure 4-3A-C) in the presence and 
absence of C.neo antigen. Consistently, MLL1 inhibition during training prevents 
γα DCs from maintaining high DC1 gene expression when challenged by pro-
DC2 cytokine environments (Figure 4-3D). Collectively, these data suggest that 
TNFα and IFNγ receptor signaling synergizes to increase MLL1 expression and 
target its activity to DC1 gene promoters. TNFα and IFNγ signaling are known 
to synergistically activate certain genes, and this has been linked to NFκB and 
STAT activation (234-236), but to our knowledge, this has not been demonstrated 
for genes of epigenetic machinery. Thus, DCs are able to remember and maintain 
robust DC1 activation throughout weeks of infection regardless of changing 
cytokine environments found in different microenvironments (i.e. regions of the 
lung, different organ systems) through MLL1-mediated H3K4 methylations, 
mechanistically linking TNFα signaling to the stable, robust DC1 phenotype, 
resulting in generation of protective Th1 immunity. 
 112 
Finally, we find that perpetuation of this stable DC1 phenotype is linked to 
TNFα-mediated epigenetic modification to the DC precursor population in the 
bone marrow during C.neo infection. In our model, we observe CD103-/CD11b+ 
DCs in the lungs exhibiting distinct characteristics of DC1 or DC2-ness based on 
the inflammatory milieu of the host, and that DC1s from the lungs of infected 
mice that had TNFα displayed a global increase in H3K4me3 relative to DCs 
from infected, TNFα-depleted mice. We see this mirrored in the bone marrow 
DC precursor populations: a) bone marrow DC precursors from infected mice 
that have TNFα have a higher global H3K4me3 signature than precursors from 
infected, TNFα-depleted mice (Figure 4-6); b) we show that the bone marrow DC 
precursor population matures ex vivo into DC1 if it was harvested from an 
infected, TNFα-containing host (Figure 4-7B, left half); and c) the bone marrow 
DC precursor population matures into DC2 if it was harvested from an infected, 
TNFα-depleted host (Figure 4-7B, right half). Thus, DCs recruited from the bone 
marrow during infection appear to arrive epigenetically pre-programmed to be 
DC1 in the presence of TNFα. There is a precedent for pre-polarization of 
myeloid cells from the bone marrow, as evidenced by Schlitzer et al. in 2015 (237). 
In their model, which utilizes a different strain of mice and a very different 
pathogen, conventional DC1 cells expressing either CD8 or CD103 become DC1 
in the bone marrow, while conventional DC2 cells expressing either CD4 or 
CD11b become DC2 polarized while in the bone marrow. This phenomenon may 
be occurring in the bone marrow during C.neo infection, and be mediated by 
TNFα and other components of the systemic inflammatory milieu. 
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In the absence of TNFα during C.neo infection in vivo, it remains unclear whether 
DCs and their precursors are subjected to epigenetic modifications and, if so, 
which genes are affected positively or negatively. Despite the recovery of TNFα 
within 14 dpi, DCs from TNFα-depleted infected mice maintain their DC2 
polarization (Figure 3-5, Figure 3-6, and Figure 3-7), suggesting that an 
alternative set of epigenetic modifications promotes the sustained DC2 gene 
expression in TNFα-depleted C.neo-infected mice. We observe a change in 
H3K4me3 signature in vivo between DC2s and immature DCs (Figure 4-1 B), and 
we show a strong trend over baseline towards H3K4me3 association with DC2 
gene Fizz1 in DC2s in vivo (Figure 4-2D). Finally, DCs developed from the bone 
marrow of infected TNFα-depleted mice resists changes to their non-DC1 
polarization by maintaining low expression of iNOS, regardless of TNCα or IFN
γ treatment (Figure 4-7B, right half). However, if DC2s from infected TNFα-
depleted mice are indeed trained DC2s, it is unclear what may be stimulating the 
training. Our in vitro model system shows that IL-4, regardless of the presence or 
absence of TNFα, is insufficient to train DC2s (Figure 3-8C and D).  
We have given much thought to the signaling pathways leading from one or 
both TNFα receptors to chromatin rearrangement machinery, in particular to 
MLL1. We assessed TNFR1 and TNFR2 expression on the surface of bone 
marrow DC precursor cells, and found slight but significant increases in surface 
expression of both TNFR1 and TNFR2 in infected control mice. In the previous 
chapter (Figure 3-13 and Figure 3-14), in vitro studies in BMDCs utilizing TNFR1, 
TNFR2, or combined TNFR1 and 2 blocking antibodies during the TNFα training 
period prevented TNFα-mediated training. TNFR1 and 2 blockade each 
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individually partially blocked training, while the combination of TNFR1 and 2 
blockade completely blocked training, suggesting that MLL1 is maximally 
induced when both TNFR pathways are stimulated. Using these findings and 
assessing TNFR expression in the bone marrow pre-DCs, we found indeed that 
the majority of TNFR-expressing cells were doubly positive for TNFR1 and 
TNFR2 expression. Mechanisms further upstream may include differential 
stimulation of MLL1 co-factors WDR5, RBBP5, and ASH2L by TNFR1 and 
TNFR2 signaling (238). NFκB, downstream of TNFR signaling, has been shown 
previously to activate MLL1 (186), which is a likely mechanism because both 
TNFR1 and TNFR2 utilize the NFκB pathway (reviewed in (239)).   
Based on our findings from this chapter and other recent work from our 
laboratory, we have assembled a model mechanism for the requirement of TNFα 
early during C.neo infection, which is detailed in Figure 5-1. Early signaling 
through TNFα receptors in DCs is necessary to classically activate DCs and to 
maintain that polarization throughout many weeks of infection, resulting in a 
long-term, stable Th1/Th17 polarized immune response. These DC1 cells 
matured in the presence of TNFα are resistant to changing their polarization– 
potentially caused by changes in cytokine environment and by immune 
modulation by C.neo– through MLL1-mediated H3K4me3 epigenetic 
modifications to the histone proteins proximal to DC1 gene promoters; in the 
absence of TNFα, C.neo antigen can polarize DCs to DC2 despite pro-DC1 
cytokine environments. DC1s activated in the presence of TNFα during infection 
traffic to the lung-associated lymph nodes, where they prime Th1 responses (Xu, 
Eastman et al. 2016, mBio, in press) and restimulate effector T cells recruited to 
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the lungs to perpetuate Th1 responses (9). Simultaneously, the inflammatory 
milieu in the lungs, combined with elevated circulating levels of TNFα, 
stimulates the bone marrow to produce and send DCs pre-polarized as DC1, 
already bearing the high H3K4me3 signature of lung DC1s. This necessity for 
long-term epigenetically-stabilized DC1 polarization in anti-cryptococcal host 
defense (and likely other pathogens that thrive in TNFα-depleted patient 
populations) suggests that immunotherapies which epigenetically re-program 
DCs or transfer in DC1s may provide long-term benefit patients suffering from 
persistent C.neo infection and prevent lethal extra-pulmonary dissemination of 
C.neo. 
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Chapter 5 Discussion 
Summary 
This dissertation has investigated afferent and efferent immune responses to the 
opportunistic pulmonary fungal pathogen Cryptococcus neoformans. Here we 
discuss mechanisms by which the afferent immune response affects the 
developing efferent response, and instances in which it does not. We then 
investigate the many ways in which TNFα and IFNγ are known to synergize, 
and how that applies to our findings from chapters 3 and 4. Finally, we place all 
of the findings from this dissertation into the broader context of antigen 
presentation and adaptive immune priming and expound upon the implications 
of this work. 
Main results: Ssa1 modulates afferent, but not efferent, macrophage activation 
In chapter 2, we used a mutant strain of the highly pathogenic strain of C.neo, 
H99 (serotype A) with a targeted deletion of the heat shock protein 70 
homologue and cryptococcal virulence factor Ssa1, Δssa1, in order to determine 
the mechanism behind Ssa1-mediated immune modulation. We first found, to 
our surprise, that Ssa1– which was necessary for the production of another 
cryptococcal virulence factor, laccase, in a strain of serotype D C.neo– was 
dispensable for the production of laccase in H99. This made assessment of Ssa1 
as a standalone virulence factor, independent of its effects on laccase, more 
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straightforward. We found that deletion of ssa1 resulted in decreased pulmonary 
fungal burden during the early/afferent, but not the later/efferent, immune 
response. This ultimately resulted in a slight but significant increase of median 
survival time in the Δssa1 infected mice. The differences in fungal control 
observed throughout the studies were linked to macrophage M1/M2 
polarization status. Macrophages stimulated with Δssa1 in vitro upregulated M1 
and downregulated M2 markers relative to H99-stimulated macrophages. 
However, while ssa1 deletion resulted in increased M1 and decreased M2 
phenotype during the afferent response in vivo, ssa1 deletion had no effect on 
macrophages in vivo during the efferent response phase, consistent with the 
improved early but not late pulmonary growth control of Δssa1. We concluded 
that Ssa1 was an virulence factor acting to promote early M2 polarization in 
isolation in vitro and in vivo, but that it ultimately had no effect on the 
development of the efferent immune response. Further, while Ssa1 itself can 
modulate macrophages early during infection, the effect of Ssa1 on macrophages 
was eventually overpowered by the immunophenotype of the efferent response, 
which is largely dependent upon DCs. Ssa1 did not promote DC2 polarization, in 
the way that it was able to promote M2 polarization, and thus had limited effects 
on the developing adaptive, efferent response.    
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Main results: Afferent TNFα  is necessary for epigenetic modifications to 
stabilize long-term DC1 programming in pulmonary DCs and bone marrow 
DC precursors, resulting in efferent Th1/Th17-polarized protective immunity 
during C.neoformans infection 
In chapters 3 and 4, we found that TNFα was necessary for long-term, stable, 
and robust Th1/Th17 immune polarization; in the absence of TNFα, a non-
protective Th2 response lasted through 4 weeks of infection, significantly 
outlasting the transient TNFα depletion (TNFα levels recovered within 14 dpi). 
We traced this defect in Th polarization to DCs: in the presence of TNFα during 
C.neo infection, there was a sustained and robust DC1 activation throughout the 
infection, which resulted in stable Th1 immunity and progressive clearance. In 
contrast, in the absence of TNFα during C.neo infection, there was a lasting DC2 
polarization that resulted in dysregulated immune responses with a strong Th2 
component and fluctuation of cytokine levels and lack of fungal clearance. 
Modeling this in vitro, we found that TNFα and IFNγ stimulation together 
result in DC1s that can resist changes in their polarization due to changing 
cytokine environments and the highly immunomodulatory C.neo antigen, called 
TNFα-trained DCs. The mechanism behind this TNFα training is epigenetic: 
TNF α -trained DCs have the activating histone modification H3K4me3 
associated with promoter regions of key DC1 genes iNOS and IL-12b in vivo, 
while this is not seen in the DC2s from TNFα-depleted infected mice. In vitro 
inhibition of MLL1, responsible for beginning the activating methylations on 
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H3K4, resulted in ablation of TNFα-mediated training of DCs. Further, we 
traced this defect in epigenetic stabilization of DC1 gene promoters to the bone 
marrow DC precursors in vivo; in the presence of TNFα during C.neo infection, 
bone marrow DC precursors undergo an increase in global H3K4me3 distinct 
from uninfected mice and TNFα-depleted, C.neo-infected mice. Bone marrow 
from C.neo-infected mice that had TNFα differentiated ex vivo into TNFα-
trained DC1, unresponsive to pro-DC2 cytokine challenge regardless of the 
presence or absence of TNFα treatment. However, DCs matured ex vivo from the 
marrow of TNFα-depleted, C.neo-infected mice maintained uniformly low DC1 
gene expression, regardless of the pro-DC1 cytokine challenge and/or the 
presence or absence of TNFα treatment. Our data led us to the conclusion that 
the stable DC1 (and the concomitant Th1/Th17) phenotype we observed in vivo 
during C.neo infection in the presence of TNFα was due to MLL1-mediated 
epigenetic modifications to H3K4 at DC1 gene promoters; in the absence of 
TNFα, MLL1 is not stimulated and these activating modifications to the histones, 
which open DC1 gene promoter regions, were not made. Further, TNFα 
signaling during C.neo infection resulted in changes to the DC precursors 
(Ly6Chigh/CD11b+ monocyte) in the bone marrow, which allowed for perpetual 
recruitment of TNFα-trained DCs and maintaining robust Th1/Th17 immune 
responses throughout infection. In the absence of TNFα during C.neo infection, 
DCs recruited from the bone marrow did not upregulate DC1 genes, thus 
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perpetuating recruitment of non-DC1s and maintaining the nonprotective Th2-
biased immune response that results in persistent C.neo infection. 
Significance: the timing of immune modulation during cryptococcosis 
The immune response to C.neo is divided up into two general, but overlapping 
phases: the afferent phase, comprised largely of innate cells containing the 
infection or exiting the site of infection to prime adaptive immune responses (2, 
10, 37, 41, 48, 151, 176, 240, 241); and the efferent phase, comprised of adaptive 
immune cells directing and facilitating microbial clearance (10, 69, 70, 72, 74, 175, 
242). The afferent phase in mice begins soon after infection and lasts until 
between 7 and 14 days post-infection (dpi), while the efferent phase begins 
slightly prior to 14 dpi when we observe several fold more pulmonary 
lymphocytes relative to 7 dpi. The research from this dissertation highlights 
important distinctions between the afferent and efferent immune responses and 
their ultimate effects on infection outcomes. In Chapter 2, the absence of the 
cryptococcal virulence factor Ssa1 increased the ability of the innate immune 
system to contain and kill the fungus at very early time points (Figure 2-1). 
However, despite this early difference in pulmonary fungal burden, the absence 
of Ssa1 did not ultimately affect host survival or clearance of the microbe during 
the later time points in a profound way. The absence of Ssa1 was sufficient to 
inhibit fungal growth early during the afferent phase, but ultimately insufficient 
to alter the resulting efferent immune response. In contrast, data from Chapters 3 
and 4 show that host TNFα was depleted with a single intraperitoneal injection 
of anti-TNFα antibody only during the afferent phase of the immune response; 
however, despite an absence of TNFα during 0-7 dpi and TNFα recovery during 
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7-14 dpi, there was no difference in pulmonary fungal burden between control 
mice and TNFα-depleted mice until 14-28 dpi, which is well into the efferent 
response (Figure 3-1). The transient depletion of TNFα  from the afferent 
inflammatory milieu was able to affect the efferent immune response for many 
weeks after TNFα levels had recovered. It is remarkable that transient TNFα 
depletion during the afferent immune response is sufficient to permanently skew 
the efferent immune response, while permanent deletion of Ssa1 only transiently 
skews the immune response. 
The differential ability of factors to affect long-term immune polarization in the 
mouse model may come down to whether or not these factors modulate the 
initial DC-mediated priming of T cells in the lymph nodes and restimulation of T 
cells in the lungs. Chapter 2 focused on the interplay of Ssa1 with macrophages 
specifically, but not DCs; we exhaustively analyzed the effect of Ssa1 on DCs but 
found that deletion of Ssa1 had little to no effect on DCs (Figure 2-10). The 
absence of the effect on DCs was surprising, considering the significant changes 
in early DC1/DC2 cytokine ratios (Figure 2-8); however, it could be explained by 
the lack of effect of Ssa1 deletion on the very low levels of TNFα during the 
afferent response in this model (Figure 2-11). Our subsequent data on the role of 
TNFα signaling, motivated in part by the findings from this chapter, indeed 
demonstrate that TNFα is required for DCs to overcome the suppressive effect 
of cryptococcal antigen and gain the ability to become DC1-polarized (Figure 
3-11). These findings contain critical implications for the immunoprotection 
against C.neo, and are discussed in greater detail below. The overall implication 
of our results from Chapter 2 are that factors sufficient to modulate DCs will 
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ultimately change the efferent response to C.neo, and ultimately have a more 
profound effect on fungal clearance during the efferent phase of the immune 
response than factors that do not.  
TNFα  and IFNγ  synergy: crosstalk and signaling pathway integration 
Throughout chapters 3 and 4, our in vitro modeling of TNFα-trained DCs 
utilizes TNFα and IFNγ in combination. We attribute TNFα-mediated training 
to epigenetic mechanisms, but the synergy of TNFRs and IFNGR signaling is a 
known phenomenon that must be acknowledged. TNFα and IFNγ are quite 
capable of inducing many inflammatory genes on their own; however, numerous 
genes are induced to a greater extent by the combination of TNFα and IFNγ, 
and the effect size is often more than an additive effect. For instance, MHC class I 
is regulated synergistically by TNFα and IFNγ in non-immune cells (243, 244), 
and in macrophages, complement factor B expression is induced by IFNγ 1.8x, 
by TNFα 1.3x, but by the combination of IFNγ and TNFα by 4.75x (245). 
Depending on the cell and model, synergy is linked to the activation and binding 
of STAT1, IRF-1, and NFκB simultaneously at each transcription factor’s binding 
sites (235, 245, 246), or a TNFα-mediated increase of IFNγ receptor surface 
expression, thus increasing the cell’s capacity for IFNγ signaling (236). In our in 
vitro model, DC1 gene upregulation by the combination of TNFα and IFNγ is 
roughly similar in magnitude to the upregulation due to IFNγ alone (Figure 
3-7,Figure 3-8,Figure 3-10), with the notable exception of DCs treated with HKC 
(Figure 3-10C and D), which were unable to upregulate DC1 genes without 
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combined TNFα and IFNγ. Thus, we attribute our stable TNFα-trained DC1 
phenotype to the chromatin modifications induced by TNFα and via MLL1, and 
we minimally attribute these effects to the synergistic enhancement of gene 
expression via transcription factor activation alone. 
In chapter 4, we show that neither MLL1 nor KDM5d are induced by TNFα or 
IFNγ stimulation alone, and only MLL1 is induced by the combination of TNF
α and IFNγ stimulation (Figure 4-3A and B).  Very little has been published 
linking TNFα and IFNγ receptor signaling synergy to chromatin modification 
machinery. CXCL10 activation, and possibly similarly regulated chemokines, in 
human airway smooth muscle cells is synergistically activated by TNFα and 
IFNγ through the action of Creb-binding protein (CBP), which possesses histone 
acetyltransferase activity (234). When we assessed levels of CBP both in vivo and 
in vitro, we found no differences at the transcriptional level between DC1, DC2, 
and TNFα-trained DCs (data not shown). Synergy from the IFNγ receptor and 
TLRs has been implicated in stabilization and perpetuation of many 
inflammatory genes, such as TNFα, IL-6, IL-12b (247). However, in our in vitro 
model in the presence of HKC, IFNγ-alone stimulated DCs are unable to 
upregulate DC1 genes (including IL-12b Figure 3-10C); IL-12b induction in the 
presence of HKC is only induced when IFNγ and TNFα are both added.  
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Greater question of DC biology 
The work from chapters 3 and 4 of this dissertation links the common pro-
inflammatory cytokine TNFα to a unique state of DC activation where, even in 
the absence of antigen, DCs are able to maintain a polarization in the face of 
changing cytokine environments. As we show in vitro in Chapter 3, activated 
DC1s can either maintain plasticity of their polarization, adapting with their 
changing cytokine environments, or they can maintain robust expression of DC1 
genes despite changing cytokine environments. In Figure 4-6 and Figure 4-7, we 
link infection and systemic TNFα to modulation of the polarization of the bone 
marrow DC precursor population. As recently as 2003, the idea that DC subsets 
developing within the bone marrow could be modulated by the inflammatory 
milieu of the body was controversial (166). There are few studies characterizing 
the modulation of developing bone marrow DC populations; however, in 
addition to recent work by Schlitzer et al. characterizing specific subsets of DC1 
and DC2 cells developing within the bone marrow (237), the sepsis field has also 
characterized this phenomenon, relating it specifically to the generation of 
broadly immunosuppressive DCs (226). In certain pathologies (i.e. sepsis), this 
results in long-term immune suppression, which can be ultimately detrimental 
for the host; however, in an infection model that lasts weeks, such as C.neo, 
maintenance of DC phenotype is necessary for the perpetuation of protective 
immunity, and ultimately benefits the host.  
This topic of epigenetic modification to immune cell precursors has been the 
subject of a number of recent reviews addressing the potential for 
immunotherapies to preferentially differentiate specifically polarized DC subsets 
 125 
in patients with sepsis-induced immune dysfunction (248) and how the 
microbiome influences myeloid subset development and polarization (249, 250). 
Thus, there is also potential for immunotherapies to change DC subset 
differentiation and polarization within the bone marrow, either for treatment 
purposes during chronic fungal infections (i.e. C.neo) with underlying immune 
polarization defects or prophylactically at the onset of other immune therapies 
(i.e. TNFα monoclonal antibody therapy). We have shown that transfer of 
epigenetically stable TNFα -trained DC1s is sufficient to overcome the 
recruitment of pre-DC2s from the bone marrow of TNFα-depleted C.neo-
infected mice and prime Th1 immune responses (Figure 3-12). Harvest, training, 
and reintroduction of ex vivo-TNFα-trained syngeneic DCs to a patient with 
chronic C.neo infection, possibly coupled with future epigenetic modification 
therapies to erase or write particular modifications in DC precursor cells in the 
bone marrow, may eliminate the need for extensive pharmaceutical intervention, 
instead relying on transfer and continued recruitment of trained DCs to re-
polarize the pulmonary immune environment. 
Unanswered questions and future directions: the role of repressive 
modifications in TNFα-trained DCs 
In Chapter 4, we have shown that TNFα signaling results in MLL1-mediated 
H3K4 methylation at the DC1 gene promoters iNOS and IL-12b. We also show 
that there is decreased H3K4me3 at the Fizz1 gene promoter in TNFα-trained 
DCs. This decrease in H3K4me3 correlates to the decrease in Fizz1 mRNA 
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expression in TNFα-trained DCs; however, we have not assessed whether Fizz1 
and other DC2 genes are epigenetically repressed in TNFα-trained DCs, nor do 
we have clues at to the modification machinery involved (for instance, by DNA 
methylation or repressive histone modifications like H3K27me3). There is a high 
likelihood of repressive modifications to DC2 genes in TNFα-trained DC1s, 
because they achieved a stable state of down-regulated of certain DC2 genes 
even upon challenge with the pro-DC2 cytokine IL-4. We found that this is not a 
general desensitization (or lack of IL-4 receptor expression) because some genes 
such as Arg1 do respond to IL-4 challenge (Table 3-1), while other DC2 genes 
remain silenced. In the future, this could be addressed using in vitro TNFα-
trained DC1s and untrained DC2s for ATAC-seq to first determine whether DC2 
genes are found in open chromatin or not. If DC2 genes are decreased in open 
chromatin, we could then perform ChIP-PCR using antibodies against selected 
common repressive histone modification marks, such as H3K27me3, or 
performing sodium bisulfate sequencing to assess whether there is increased 
DNA methylation at DC2 gene regions. Upon determining which repressive 
modifications are involved in TNFα-mediated DC2 gene repression, we could 
then screen for which predicted enzymes of epigenetic modification machinery 
are upregulated at the transcriptional level, increased at the protein level, and 
finally pharmacologically inhibit candidate enzymes to assess whether inhibition 
of their biological activity ablates TNFα-mediated DC2 gene repression upon IL-
4 challenge. This work would be complementary to our findings that TNFα 
epigenetically activates DC1 genes by MLL1, and may be necessary for the 
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optimal function of the proposed immunotherapies that might target epigenetic 
memory of DCs and/or their myeloid precursors in the bone marrow. Activation 
of DC1 genes in TNFα-trained DCs by MLL1 is only half of the picture, while 
the concurrent repression of DC2 genes is likely equally important in generation 
of the robust and stable DC1 polarization. We need to figure out and better 
understand how epigenetic modifications to DCs result in priming and 
maintenance of protective T cell-mediated immune responses to C.neo in vivo. 
Unanswered questions and future directions: epigenetic modifications to DCs 
during C.neoformans infection in the absence of TNFα  
In the absence of TNFα during C.neo infection in vivo, we found that DCs are 
alternatively activated, and they prime and restimulate Th2/Treg responses 
throughout 4 weeks of infection (Chapter 3). These DCs do not bear the high 
H3K4me3 signature that we see in TNFα-trained DCs, nor do they upregulate 
MLL1. However, we show that DCs matured ex vivo from TNFα-depleted, 
C.neo-infected mice are resistant to changing polarization upon cytokine 
challenge, similar to the TNFα-trained DCs but opposite in the direction of their 
gene expression. While TNFα-trained DCs matured ex vivo from infected hosts 
were uniformly programmed to be DC1 and resist changes in polarization from 
pro-DC2 cytokines, untrained DCs matured ex vivo from TNFα -deficient 
infected hosts were uniformly programmed to be DC2, resisting changes in 
polarization from pro-DC1 cytokines (Figure 4-7B). It is unclear if this is a 
directed activation and epigenetic stabilization of DC2 genes, or whether the 
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DC2 polarization could be thought of as the default polarization, and epigenetic 
modifications solidify and perpetuate this programming. We can see that 
untrained DCs from TNFα-depleted infected mice had a decrease in H3K4me3 
association with the DC1 gene promoters iNOS and IL-12b relative to control 
mice (Figure 4-2A and B), which implies active demethylation at H3K4me3 in 
these regions. Furthermore, untrained DC2 have a trend towards increased 
H3K4me3 association with the Fizz1 promoter region relative to controls, which 
suggests active methylation in this region. Taken together, these data support the 
epigenetic suppression of DC1 genes and epigenetic activation of DC2 genes in 
untrained DC2s in vivo. We know from Figure 3-7C and D that TNFα is not a 
stabilizing factor for DC2 programming in vitro, but it remains unclear what may 
be acting as a stabilizing factor in vivo. Continued in vitro modeling using other 
dominant cytokines found during the afferent phase of the immune response to 
C.neo in the absence of TNFα may help address this question. Additionally, 
cryptococcal antigen may be responsible for inducing– alone or synergistically 
with other cytokines– epigenetic or other transcriptional programming changes 
to DCs and their bone marrow precursor populations. We have limited evidence 
for increased EZH2 activity and H3K27me3 in DC2 cells, both in vitro and in vivo, 
but these studies are ongoing. Similarly, we have found that JMJD3 is 
differentially expressed in TNFα-trained DC1 and DC2 in vitro and between 
DC1 and DC2 in vivo. This dissertation has addressed the mechanism by which 
afferent phase TNFα  perpetuates protective immunity to persistent C.neo 
infection, but it is beyond its scope to determine mechanistically how DCs in the 
absence of TNFα during C.neo infection perpetuate their DC2 polarization.  
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Final thoughts 
In this doctoral dissertation, I have shown that while the afferent immune 
response can dramatically and permanently affect the developing efferent 
immune response to C.neo, perturbations to the afferent response do not 
necessarily result in concomitant efferent changes. Phagocytes can control C.neo 
to a greater and lesser extent early during infection, but the actions of DCs that 
prime the T cell response ultimately control the outcome of infection. If DCs are 
unaffected by a particular virulence factor, its absence doesn’t necessarily 
ultimately correlate to increased protection (see: Ssa1). However, if DCs are 
activated towards DC2, or remain immature (84), or if cryptococcal virulence 
factors suppress crucial early host cytokine production (88), the result is 
generation and perpetuation of a non-protective immune response that 
ultimately results in persistence and, typically, eventual progressive 
extrapulmonary dissemination of C.neo. Thus, afferent-phase cytokine (i.e. TNF
α) modulation of DC polarization (i.e. via epigenetic mechanisms) can control 
the development of anticryptococcal CD4 T cell-mediated immunity, and is likely 
an important mechanism in a broad range of host-pathogen interactions. 
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Figure 5-1 A final model: TNFα  is necessary for generating robust and stable DC1 expression during 
C.neo infection, thus priming and perpetuating Th1/Th17 protective T cell-mediated immunity.  
 
TNFα– in combination with the inflammatory milieu of the C.neo-infected lung– 
primes DCs to adopt DC1 polarization. TNFα signaling activates MLL1, which 
adds activating methyl groups to H3K4 at promoter regions of DC1 genes. These 
robust and stable DC1s traffic to the lung-draining lymph node where they 
prime Th1/Th17 immune responses, while remaining and recruited pulmonary 
DC1s restimulate the Th1/Th17 T cells in the lung throughout infection. 
Pulmonary DC1s are replenished via DC recruitment from the bone marrow, 
where the TNFα signaling and other inflammatory mediators have modified the 
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proliferating bone marrow DC precursor population, resulting in recruitment of 
pre-polarized DC1s to the infected lung. In the absence of TNFα during the 
afferent response to C.neo infection, DCs don’t receive epigenetic stabilization to 
DC1 genes through TNFα and MLL1. Due to the lack of epigenetic stabilization 
of DC1 genes, and the immunomodulatory effect of cryptococcal antigen (known 
to promote DC2 activation), DCs polarize to DC2, traffic to the lymph node, 
prime non-protective Th2 responses, and remaining/recruited pulmonary DC2s 
restimulate the Th2 T cells in the lung throughout infection. The lack of TNFα in 
combination with other inflammatory mediators during C.neo infection modifies 
the proliferating bone marrow DC precursor population, resulting in recruitment 
of pre-polarized DC2s to the infected lung and the perpetuation of non-
protective T cell-mediated immunity.  
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Chapter 6 Materials and Methods 
Methods common to all chapters 
Intratracheal inoculation of C. neoformans 
Mice were anesthetized with intraperitoneal injection of ketamine/xylazine 
(100/6.8 mg/kg body weight) and were secured onto a clean foam board. Hair 
was removed from over the trachea and skin was sterilized with iodine and 
ethanol. A small incision was made over the trachea, and the underlying muscle 
and glands were separated to expose the trachea. A 30-gauge needle was 
inserted into the trachea and 30 µl (104 CFU) of the washed yeast (3.3 × 105 yeast 
cells/ml in sterile non-pyrogenic saline) were injected intratracheally from a 1-ml 
tuberculin syringe fitted to a stepper pipette. After inoculation, the incision was 
closed with cyanoacrylate adhesive, and mice were kept warm and monitored 
during recovery from anesthesia. 
Serum preparation 
Mice were humanely euthanized by CO2 asphyxiation, then exsanguinated to 
confirm death. Whole blood was collected in eppendorf tubes, spun down to 
consolidate blood, allowed to rest at room temperature for 20 minutes. Blood 
was then incubated at 4°C for 20 minutes, then centrifuged at 5000 RPM to 
separate serum from erythrocytes. The top serum layer was collected and frozen 
at -80°C until ELISA or cytometric bead array for cytokine analysis. 
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Lung leukocyte isolation 
At the time of data collection, lungs were perfused with 3 ml sterile 
nonpyrogenic saline, removed, washed in RPMI 1640, and enzymatically 
dispersed as previously described (176, 251). Briefly, excised lungs from each 
mouse were minced with scissors and digested enzymatically at 37°C for 30 min 
in 5 ml/mouse digestion buffer (RPMI 1640, 5% FBS, penicillin and streptomycin 
[Invitrogen, Grand Island, NY]; 1 mg/ml collagenase A [Roche Diagnostics, 
Indianapolis, IN]; and 30 mg/ml DNase [Sigma]). The cell suspension and tissue 
fragments were further dispersed by repeated aspiration through the bore of a 
10-ml syringe and centrifuged. Erythrocytes in the cell pellets were lysed by 
addition of 3 ml NH4Cl buffer (0.829% NH4Cl, 0.1% KHCO3, and 0.0372% 
Na2EDTA, pH 7.4) for 3 min followed by a 10-fold excess of RPMI 1640. Cells 
were resuspended and a second cycle of syringe dispersion and filtration 
through a sterile 100-mm nylon screen (Nitex, Kansas City, MO) was performed. 
The filtrate was centrifuged for 25 min at 1500 × g in the presence of 40% Percoll 
(Sigma) in complete RPMI 1640 (RPMI 1640, 5% FBS, 10 U/ml penicillin and 
streptomycin [Invitrogen, Grand Island, NY], 1X sodium pyruvate, 1X glutamax, 
1X non-essential amino acids, 2-mercaptoethanol) with no brake to separate 
leukocytes from cell debris and epithelial cells. Leukocyte pellets were 
resuspended in 5 ml complete RPMI 1640 media and enumerated on a 
hemocytometer after dilution in trypan blue (Sigma).  
CFU assay 
For determination of fungal burden in the lungs, 100 %l was removed from the 
enzymatically dispersed lungs prior to centrifugation and 10-fold dilutions were 
 134 
plated in duplicate on Sabouraud dextrose agar plates. For determination of 
brain CFU, brains from mice in the survival study were removed at the time of 
death and homogenized in 2 ml sterile mili-Q water. 10-fold dilutions were then 
plated in duplicate on Sabouraud dextrose agar plates. Colonies were counted 
after 48 h of growth at room temperature, and CFU was calculated on a per-
organ basis. For determination of spleen CFU, spleens were removed at the time 
of death and homogenized in sterile mili-Q water. 10-fold dilutions were then 
plated in duplicate on Sabouraud dextrose agar plates. Colonies were counted 
after 48 h of growth at room temperature, and CFU was calculated on a per-
organ basis. 
Preparation and enumeration of lung leukocytes 
Following enzymatic dispersal of the lungs, 50,000 cells were cytospun onto glass 
slides, fixed, stained with Wright-Giemsa stain, and dried. Monocytes, 
eosinophils, neutrophils and lymphocytes were counted as described previously 
(252).   
Flow cytometry 
Enzymatically dispersed lungs were counted and stained extracellularly, then 
fixed, permeabilized, and stained intracellularly as previously described (49), 
then run on an LSR II flow cytometer using FACSDiva software (BD Biosciences, 
San Jose, CA) and analyzed further using FlowJo software (Tree star, San Carlos, 
CA). Gating for lung myeloid cells proceeded as follows: the CD45+ cells were 
identified, lymphocytes were removed (CD19+/CD3+), neutrophils were 
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removed (Ly6G+/CD11b+), eosinophils were excluded (SSChigh/CD11cint), and 
then CD11c+ (myeloid cells) or CD11b+/CD11c+ (DCs) cells were analyzed for 
expression of activation markers. Gating for lung CD4 T cells proceeded as 
follows: the CD45+ cells were identified, cells were selected on CD3+, and 
CD19/CD11b/CD11c+ cells were excluded. T cells were then gated on CD4 vs 
CD8 expression, and the CD4 single positive population was analyzed for 
surface activation marker expression and intracellular expression of Th 
polarization cytokines. Intracellular and intranuclear staining was performed 
using the FoxP3/Transcription Factor Staining Buffer kit from eBiosciences (San 
Diego, CA, USA). For specific antibodies, see each respective methods section. 
Real-Time PCR 
Cells were spun down and directly resuspended in 1 ml Trizol reagent (Life 
Technologies, Inc., Gaithersburg, MD) in polypropylene tubes. Samples were 
allowed to incubate at room temperature, and 200 %l chloroform per 1 ml Trizol 
was added to them. Samples were spun at 10,000 rpm for 15 min, the aqueous 
phase was transferred into fresh tubes, and equal volumes of isopropanol were 
added. Samples were then incubated at -20°C for 90 minutes to precipitate the 
RNA and centrifuged again as described above. Pellets were washed with 1 ml of 
70% ethanol and centrifuged. RNA was resuspended in nuclease-free water. The 
yield and purity of the RNA were determined spectrophotometrically at 260 and 
280 nm. cDNA was synthesized using QuantiTect Reverse Transcription Kit 
(Qiagen, Valencia, CA) using 1 %g RNA according to the manufacturer’s 
instructions. cDNA was quantified with SYBR Green– based detection using an 
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MX 3000P system (Stratagene, La Jolla, CA) according to the manufacturer’s 
protocols. Forty cycles of PCR (94°C for 15 seconds followed by 60°C for 30 
seconds and 72°C for 30 seconds) were performed on a cDNA template.  
Statistical analysis 
All values are reported as means ± SEM. Continuous ratio scale data were 
evaluated by unpaired Student’s t-test (for comparison between two samples) or 
by ANOVA (for multiple comparisons) with post hoc analysis using Student’s t-
test with Bonferroni adjustments. Non-parametric analysis was performed using 
the Kruskal-Wallis, Kolmogorov-Smirnov, or Mann-Whitney tests. Survival 
study comparisons were performed using Kaplan-Meier analysis. Statistical 
calculations were performed on a PC computer using GraphPad Prism version 
6.00 for Windows (GraphPad Software, San Diego, CA). Statistical difference was 
accepted at p < 0.05. 
Methods for experiments from Chapter 2 
Mice 
6-8 week old female Balb/c mice were obtained from Jackson Labs and were 
housed at the Veterinary Medicine Unit at the Ann Arbor Veterans 
Administration Hospital. Mice were aged to 8-10 weeks old at the time of 
infection. At the time of data collection, mice were humanely euthanized by CO2 
inhalation followed by severance of the portal vein. All experiments were 
approved by the University Committee on the Use and Care of Animals and the 
Veterans Administration Institutional Animal Care and Use Committee.  
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C. neoformans 
C. neoformans serotype A strain H99 (ATCC 208821) was recovered from 10% 
glycerol frozen stocks stored at -80°C. C. neoformans mutants H99-Δssa1 and H99-
Δssa1∷SSA1 were recovered from 10% glycerol frozen stocks stored at -80°C for 
experiments. Cultures were grown at 37°C in Sabouraud dextrose broth (1% 
Neopeptone, 2% dextrose, Difco, Detroit, MI) on a shaker. When cultures reached 
mid-log phase growth (day 3 for H99, day 5 for H99-Δssa1 and H99-Δssa1∷SSA1 
when cultured from freezer stocks, at which point all strains had similar growth 
kinetics), an aliquot of culture was washed in sterile non-pyrogenic saline 
(Travenol, Deerfield, IL), counted on a hemocytometer, and diluted to 3.3 × 105 
yeast cells/ml in sterile non-pyrogenic saline. 
Generation of serotype A Δssa1 mutant and Δssa1∷SSA1 complement strain 
To make the deletion construct, a pair of PCR primers, which correspond to an 
internal sequence within the ORF of SSA1 (5′-TTCCATCACTCGTGCCCGA-3′ 
and 5-′TATACAT GTCGTGTCACAGAC-3′), was used to amplify a 1.3 kb SSA1 
genomic fragment. The PCR fragment was cloned into the pCR2.1 TA cloning 
vector (Invitrogen), and a 1.3 kb fragment of the cryptococcal selection marker 
URA5 was PCR amplified from plasmid pURA5g2 as described (129), and 
inserted into a unique AgeI site. The recovered plasmid (pSSA1URA5-1) was 
digested with EcoRI, and the deletion construct was gel purified and 
transformed into a C. neoformans H99 ura5 strain described previously (253) by 
electroporation (BioRad). Transformants were screened by PCR, and disruption 
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of SSA1 was confirmed by Southern blot using the indicated restriction enzymes 
and the product was hybridized with a 32P-labelled 1.5 kb PCR-amplified 
fragment of SSA1 that was used above to produce the SSA1 deletion construct. 
For complementation of the ∆ssa1 mutant, a 4.5 kb SSA1 PCR fragment of wild-
type DNA was amplified using 5′-
GCCGCCCTGCAGTGAGGTTGATGTGCCTTTCC-3′ and 5′-
GCCGCCATCGATATGTCCGAAAGACTATCCGGA-3′, digested with the 
appropriate restriction enzymes and ligated into compatible sites of pBS-Hyg 
(pBluscript containing the hygromycin B-resistant gene (254)). The plasmid 
(pSSA1Hyg-2) was digested with NotI and transformed into the ∆ssa1 mutant by 
electroporation and inoculated onto asparagine agar plates containing 
hygromycin. The transformant was characterized by Southern blot for SSA1 and 
Western blot for Ssa1 and laccase expression analysis. Retention of the SSA1 
deletion in the complemented strain was also confirmed by Southern blot. 
Furthermore, genomic insertion of the wild-type SSA1-HgR construct was 
confirmed by Southern blot of uncut DNA hybridized with the HgR gene (data 
not shown). 
Survival study 
6-7 mice were infected intratracheally with 104 CFU of the wild type H99, H99-
Δssa1 or H99-Δssa1∷SSA1 strains as described above. Mice were monitored daily 
for survival, and moribund animals were humanely euthanized and survival 
data recorded.  
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Assessment of laccase expression 
Cryptococcus neoformans strains H99 or H99-Δssa1 were isolated from the brains of 
infected mice at the time of death. The brain isolates and the original inoculum 
were plated on asparagine salts agar (40 g Bacto agar, 4 g Asparagine, 2 g MgSO4, 
12 g KH2PO4, 12 g glucose, 4 mg thiamine, 4 mM polyphenol per liter in ddH2O). 
Melanin production, indicative of laccase expression, results in brown to black-
colored colonies, while deficiency in laccase expression results in pale colonies 
when incubated for 3-7 days at room temperature. 
Flow cytometry 
For flow cytometry experiments, Abs were purchased from BioLegend (San 
Diego, CA), including rat anti-murine CD16/CD32 (Fc block), rat anti-murine 
CD45 conjugated to allophycocyanin, hamster anti-murine CD11c conjugated to 
Pacific blue, rat anti-murine CD11b conjugated to allophycocyanin-Cy7, rat anti-
murine Ly6G conjugated to PE-Cy7, rat anti-murine CD3 or CD19 conjugated to 
PerCPCy5.5, rat anti-murine CD206 conjugated to FITC, and rat anti-mouse 
Galectin-3 or MHC class II (2A/IE) conjugated to PE. 
RT-qPCR 
The primers used are described in Table 6-1. The mRNA levels were normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels and 
relative expression shown as % of GAPDH. 
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Table 6-1: Primers used in Chapter 2. 
Histology  
Lungs were instilled with 1 ml of 10% neutral buffered formalin, excised, 
immersed 10% in neutral buffered formalin and embedded in paraffin as 
described previously (46). 5 µm sections were cut and stained with H&E and 
mucicarmine counterstain. Sections were analyzed with light microscopy and 
microphotographs were taken using Digital Microphotography system DFX1200 
with ACT-1 software (Nikon, Tokyo, Japan). 
Fluorescence microscopy 
Lungs were inflated and prepared as previously described (71). Sectioning and 
staining were performed as follows: Serial frozen tissue sections were cut at a 
thickness of 10 %m and fixed at −20°C in acetone for 10 min. Tissue sections were 
rehydrated in 70% ethanol for 5 min and washed in PBS for 3 min. Sections were 
blocked in normal rabbit or rat serum, depending on the species in which the 
primary staining antibodies used were generated. Antibodies used were rabbit 
anti-mouse Arg-1 (Santa Cruz Biotechnology, Santa Cruz, CA), rat anti-mouse 
CD206 (macrophage mannose receptor, AbD Serotec, Raleigh, NC), and rabbit 
anti-mouse inducible nitric oxide synthase (iNOS, Axxora, San Diego, CA). 
Primary antibodies were detected using Alexa 488-conjugated goat anti-rat IgG 
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or goat anti-rabbit IgG secondary antibodies (Invitrogen, Carlsbad, CA). Tissue 
sections were incubated overnight at 4°C with primary Abs diluted in species-
specific serum (3% in PBS) at pre-optimized concentrations. Subsequently, the 
sections were washed five times in Tris-NaCl-Tween 20 (TNT) buffer solution for 
3 min each. Sections were then incubated with secondary Abs for 30 min at room 
temperature. Slides were washed five times in TNT buffer for 3 min each, once in 
PBS containing 1% Triton X-100 to minimize background fluorescence (5 min), 
and given a final wash in TNT buffer (3 min). Sections were then mounted with 
FluorSave reagent (Calbiochem, La Jolla, CA) containing 0.3 %M DAPI 
(Molecular Probes, Eugene, OR). Fluorescence was visualized with a Leica DMR 
epifluorescence microscope (Leica Microsystems, Wetzlar, Germany). Images 
were acquired using a cooled Spot RT charge-coupled device camera (Diagnostic 
Instruments, Sterling Heights, MI). Imaging acquisition was done using the auto 
exposure setting within the software package and evaluating each specimen 
using these consistent conditions, and imaging analysis was performed using 
IPLab v4.08 (BD Biosciences).   
Methods for experiments from Chapters 3 and 4 
Mice 
6-8 week old female CBA/J mice were obtained from Jackson Labs and were 
housed at the Veterinary Medicine Unit at the Ann Arbor Veterans 
Administration Hospital. Mice were aged to 8-10 weeks old at the time of 
infection. At the time of data collection, mice were humanely euthanized by CO2 
inhalation followed by severance of the portal vein. All experiments were 
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approved by the University Committee on the Use and Care of Animals and the 
Veterans Administration Institutional Animal Care and Use Committee.  
C. neoformans 
C. neoformans strain 52D  (ATCC 24067)was recovered from 10% glycerol frozen 
stocks stored at -80° C. Cultures were grown at 37°C in Sabouraud dextrose 
broth (1% Neopeptone, 2% dextrose, Difco, Detroit, MI) on a shaker. When 
cultures reached mid-log phase growth (day 3 for 52D), an aliquot of culture was 
washed in sterile non-pyrogenic saline (Travenol, Deerfield, IL), counted on a 
hemocytometer, and diluted to 3.3 × 105 yeast cells/ml in sterile non-pyrogenic 
saline. 
Cytometric bead array 
Cytokine levels were analyzed by LegendPLEX T helper cytokine and 
Inflammation panels. Serum from whole blood and standard curve was diluted 
in Matrix C reagent and stained as per manufacturers instructions (BioLegend, 
San Diego, CA). Bead-antibody-protein complexes were fixed and run on an 
LSRII flow cytometer using FACSDiva acquisition software. Results were 
analyzed using software included with LegendPLEX kits. 
Magnetic cell separation 
From enzymatically digested lungs, lung leukocytes were first labeled with anti-
CD4 antibody and magnetically sorted per manufacturers instructions (Stemcell 
Technologies, Vancouver, BC, Canada). Recovered CD4 cells were pelleted and 
lysed in Trizol. Flow-through from CD4 sorting was saved, and flow-through 
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was re-labeled with anti-CD11c antibody and magnetically sorted again. 
Recovered CD11c cells were pelleted and lysed in Trizol.  
Generation of Bone Marrow-derived DCs 
Uninfected mice were humanely euthanized and death confirmed by 
exsanguination. Two femurs and two tibias were isolated from each mouse, 
washed in 70% ethanol, then epiphyses were removed and marrow flushed with 
D20 media (DMEM + 20% FBS, 1 U/ml penicillin and streptomycin [Invitrogen, 
Grand Island, NY], 1X sodium pyruvate, 1X glutamax, 1X non-essential amino 
acids, 2-mercaptoethanol, 20 nM GM-CSF) using 26 gauge needles. Cells were 
pelleted, resuspended in D20, and grown in sterile, non-tissue-culture-treated 
150mm petri dishes for 7 days. Media was replenished with D20 on day 3. After 7 
days, the loosely adherent fraction was harvested in PBS, pelleted, counted, and 
plated in non-tissue-culture-treated 6-well dishes at a concentration of 2 x 106 
cells/well. For an experimental schematic, see Figure 6-1. For the training phase, 
IFNγ was used at a concentration of 100 ng/ml, TNFα was used at a 
concentration of 20 ng/ml, and cells were incubated for 24 hours. For the 
challenge phase, training phase media was aspirated and wells were washed 
with sterile PBS, and challenge media containing IL-4 was used at a 
concentration of 20 ng/ml, while IFNγ control-challenge media was at the same 
concentration as above. For experiments using heat-killed C.neo, cultures of 
strain 52D were counted, diluted to 2 x 108 CFU/mL, and heat killed by 
incubating at 65°C for 6 hours. Heat-killed cultures were added to the BMDCs at 
an MOI of 10 during the training phase for 24 hours, and washed out prior to the 
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challenge phase. For experiments utilizing TNFR1 and/or TNFR2 blockade, 
sterile validated LEAF-purified blocking antibodies for TNFR1 and TNFR2 were 
purchased from BioLegend and used at a concentration of 10 %g/ml for 24 hours 
during the training phase and washed out prior to the challenge phase. For 
experiments utilizing MM102 (Tocris, Bristol, UK), the inhibitor of MLL1, it was 
used at a concentration of 50 %M during the training phase for 24 hours and 
washed out prior to challenge. For media-only and TNFα-only control wells 
(utilizing same TNFα concentration as above), cells were incubated 24 hours in 
their respective media, washed identically to experimental wells, and further 
incubated 24 hours in plain media. 
For ex vivo BMDC experiments utilizing marrow from infected or uninfected 
control or TNFα-depleted mice, 4 femurs from each group were isolated and 
marrow was prepared as above at 7 dpi, taking care to keep each condition 
separate. Cytokine cycling experiments were performed exactly as above. 
In each condition, after the 24 hour challenge phase, media was aspirated and 
cells were either lysed in 1ml Trizol or incubated with cold PBS on ice and gently 








For CD4 cells, T helper differentiation qPCR arrays with 96 genes per sample 
were purchased from SA Biosciences (Qiagen) and used initially, while 
individual RT-qPCR reactions were performed later to confirm and expand 
analyzed genes. For CD11c cells, custom qPCR arrays with 48 genes per sample 
were used initially, while individual RT-qPCR reactions were performed later to 
confirm and expand analyzed genes. RNA was converted to cDNA as described 
above and mixed with nuclease-free water and master mix according to 
manufacturer’s instructions. Data was analyzed using the 2-ddct method using β-
actin as housekeeping control gene and each sample normalized to uninfected 
control. Data and heatmaps were prepared using Excel (Microsoft, Redmond, 
WA, USA).  
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For BMDC experiments, RT-qPCR was performed as described above using the 
primers listed below in Table 6-2. Each sample was run in duplicate and ct values 
were averaged before performing calculations. 18s was used as the housekeeping 
control gene and each sample was normalized to media only-treated BMDCs. 
Gene Sense primer Antisense primer 
18s GAGGCCCTGTAATTGGAATGAG GCAGCAACTTTAATATCCGCTATTGG 
iNOS TTTGCTTCCATGCTAATGCGAAAG GCTCTGTTGAGGTCTAAAGGCTCCG 





MHCII GCGACGTGGGCGAGTACC CATTCCGGAACCAGCGCA 
CD206 CTCTGTTCAGCTATTGGACGC CGGAATTTCTGGGATTCAGCTTC 
IL-12b GGAAGCACGGGGAGCAGAATA AACTTGAGGGAGAAGTAGGAATGG 










Fizz1 (promoter) TGCAATTCTTTGATGCTGTGTCT AGCACCCTCAACCCAAAGTG 
KDM5c GACCCATCGCCGAGAAGTC TCGGGGAGTAAACCTGAAGTT 
MLL1 ATCCTCTCAGACCCATCTGTGT GTAGGAGGTCTTCCTCTCTTC 
   
Table 6-2 Primers used in Chapters 3 and 4. 
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Flow Cytometry 
Antibody Clone Vendor 
IFNγ XGM1.2 Biolegend 
IL-17 TC11-18H10.1 Biolegend 
IL-13 eBio13A eBiosciences 
TNFα MP6-XT22 Biolegend 
MHCII 11-5.2 BD Biosciences 
CD86 GL-1 Biolegend 
CD206 C068C2 Biolegend 
Gal3 eBioM3/38 Biolegend 
H3K4me3 MABI 0304 Active Motif 
CD45 30-F11 Biolegend 
CD3ε  145-2C11 Biolegend 
CD19 6D5 Biolegend 
CD11b M1/70 Biolegend 
CD11c N418 Biolegend 
Ly6C HK1.4 Biolegend 




SCA-1 D7 Biolegend 
Flt-3 A2F10 Biolegend 
c-kit 2B8 Biolegend 
CD115 AFS98 Biolegend 
CD4 GK1.5 Biolegend 
CD8 53-6.7 Biolegend 
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Table 6-3 Flow cytometry antibodies used in chapters 3 and 4. 
Antibodies for intranuclear staining of H3K4me3 were conjugated in house using 
PE-Cy7 conjugation kit according to the manufacturer’s protocol (Abcam, 
Cambridge, UK). Gating schemes can be seen for pulmonary CD4 T cells (Figure 
6-2), pulmonary DCs (Figure 6-3), and bone marrow myeloid precursor cells and 
pre-DCs (Figure 6-4) below. 
 
Figure 6-2 Gating scheme for pulmonary CD4 T cells: CD45+/CD3+/B220-/CD11b-/CD11c-/CD4+. 
 
Figure 6-3 Gating scheme for lung dendritic cells: CD45+/Fschigh/CD3-/CD19-/CD11b+/CD11chigh. 
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Figure 6-4 Gating scheme for bone marrow myeloid precursor cells and pre-DCs: CD3/CD19-/CD4-/Ly6G-
/SCA-1-/Flt3+/CD115+; pre-DCs were further gated on c-kitlow. 
Adoptive transfer 
At day -7, BMDCs were generated as described above, differentiated over 7 days, 
and on day 0, the loosely-adherent fraction was plated as described above and 
stimulated for 24 hours with TNFα and IFNγ in combination (γα) to generate 
TNFα-trained DC1s, or with IFNγ alone (γ-alone) to generate untrained DC1s. 
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On day 0, CBA/J mice were inoculated i.t. as above with C.neo 52D and TNFα-
depleted by i.p. injection of TNFα-blocking antibody. On day 0, another set of 
BMDCs were generated and differentiated as described above for 7 days. On day 
1, 1 million γα DCs or γ-only DCs in plain PBS were injected i.v. through the 
retro-orbital route into the C.neo-infected, TNFα-depleted mice. On day 7, the 
loosely-adherent fraction of the second set of BMDCs were harvested, plated, 
and stimulated for 24 hours with γα or γ-alone. On day 8, a second retro-
orbital injection of 1 million γα or γ-alone DCs were transferred as described 
above (for schematic, see Figure 3-12A). Mice were harvested at 14 dpi and the 
CD4 T cells assessed for Th polarization by intracellular flow cytometry. 
Chromatin immunoprecipitation and qPCR 
ChIP was performed using the protocol from the laboratory of Dr. Yali Dou at 
the University of Michigan Department of Pathology. Briefly, magnetically 
separated CD11c+ cells were isolated from the lungs of mice at 14 dpi and fixed 
in formaldehyde at a final concentration of 1%. The fixation was stopped with 
5M glycine, and cells were pelleted, the supernatant aspirated, and pellets frozen 
at -80°C until 25-30 x 106 cells per treatment were accumulated. Cells were 
thawed and lysed in SDS lysis buffer (1% SDS, 10mM EDTA, 50mM Tris pH 8.0, 
1x complete protease inhibitor cocktail), homogenized by aspiration through a 
27-gauge needle twice. Cells were sonicated on ice in a Bioruptor using the 
highest setting for 15 minutes with 30 sec on/30 sec off cycles. Sonication 
efficiency and chromatin shearing was assessed by running a small aliquot of 
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sample on 1% agarose gel before proceeding. Reactions were centrifuged to 
pellet debris, and supernatant removed and diluted in ChIP dilution buffer 
(0.01% SDS, 1.1% TritonX-100, 1.2mM EDTA, 16.7mM Tris-HCL pH 7.5, 167mM 
NaCl, 1x complete protease inhibitor cocktail). 1% input fraction was removed 
here, then diluted lysate was aliquotted to eppendorf tubes and antibodies were 
added at a concentration of 2.5 ug. Reactions were incubated over night rotating 
at 4°C. For immunoprecipitation, 30 ul protein G Dynabeads (Life technologies, 
Carlsbad, CA, USA) were used for each reaction. Reactions were washed with 
increasingly stringent washes: low salt wash buffer (0.1% SDS, 1% TritonX-100, 
2mM EDTA, 20mM Tris-HCL pH 7.5, 150 mM NaCl), high salt wash buffer (0.1% 
SDS, 1% TritonX-100, 2mM EDTA, 20mM Tris-HCL pH 7.5, 500 mM NaCl), LiCl 
wash buffer (0.25M LiCl, 1% NP-40, 1% deoxycholic acid, 1mM EDTA, 10mM 
Tris-HCK pH 7.5), and TE wash buffer (10mM Tris0-HCL pH 7.5, 1 mM EDTA). 
Finally, antibody-protein-DNA complexes were eluted using elution buffer (1% 
SDS, 0.5mM NaHCO3) and heated at 37°C for 1 hour. Crosslinking was reversed 
by addition of 5M NaCl and incubated overnight at 65°C. DNA was purified 
using phenol chloroform extraction and isopropanol precipitation. qPCR was 
performed as described above, using recovered genomic DNA as the template, 
and primers specific to the promoter regions of β-actin, Fizz, iNOS, and IL-12b.  
Fluorescence microscopy 
CD11b+ pre-DCs were isolated from the bone marrow of isotype or TNFα-
depleted infected and control mice by magnetic bead separation as described 
above according to the manufacturer’s protocol. Cells were washed and counted, 
then 20,000 cells were cytospun onto charged glass microscope slides, fixed, and 
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stained with primary antibodies against H3K4me3 (Active Motif, Carlsbad, CA) 
and Fizz1 (R&D Systems, Minneapolis, MN) or control IgG (R&D Systems), and 
then stained using anti-rabbit AlexaFluor 594 or anti- goat AlexaFluor 488 
secondary antibodies, and mounted with VECTASHIELD mounting media plus 
DAPI (Vector laboratories, Burlingame, CA, USA). Slides were visualized by 
confocal microscopy using a spinning disk confocal microscope (Olympus 
America Inc., Center Valley, PA) with a digital CCD camera (Hamamatsu 
Photonics, Hamamatsu, Japan) for image capture and an arc lamp illumination 
source providing excitation wavelengths of 350 to 700 nm and three-color 
emission analyses. The acquired digital images were processed and analyzed 
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